###begin article-title 0
Transcription factor C/EBPbeta isoform ratio regulates osteoclastogenesis through MafB
###end article-title 0
###begin p 1
These authors contributed equally to this work
###end p 1
###begin p 2
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits distribution, and reproduction in any medium, provided the original author and source are credited. This license does not permit commercial exploitation without specific permission.
###end p 2
###begin p 3
###xml 420 421 414 415 <sup>*</sup>
###xml 658 667 646 652 <italic>c/ebp&#946;</italic>
###xml 667 670 652 655 <sup>&#8722;/&#8722;</sup>
###xml 692 695 677 680 <italic>L/L</italic>
###xml 737 742 <span type="species:ncbi:10090">mouse</span>
Disequilibrium between bone-forming osteoblasts and bone-resorbing osteoclasts is central to many bone diseases. Here, we show that dysregulated expression of translationally controlled isoforms of CCAAT/enhancer-binding protein beta (C/EBPbeta) differentially affect bone mass. Alternative translation initiation that is controlled by the mammalian target of rapamycin (mTOR) pathway generates long transactivating (LAP*, LAP) and a short repressive (LIP) isoforms from a single C/EBPbeta transcript. Rapamycin, an inhibitor of mTOR signalling increases the ratio of LAP over LIP and inhibits osteoclastogenesis in wild type (WT) but not in C/EBPbeta null (c/ebpbeta-/-) or in LIP knock-in (L/L) osteoclast precursors. C/EBPbeta mutant mouse strains exhibit increased bone resorption and attenuated expression of MafB, a negative regulator of osteoclastogenesis. Ectopic expression of LAP and LIP in monocytes differentially affect the MafB promoter activity, MafB gene expression and dramatically affect osteoclastogenesis. These data show that mTOR regulates osteoclast formation by modulating the C/EBPbeta isoform ratio, which in turn affects osteoclastogenesis by regulating MafB expression.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 113 138 113 138 <xref ref-type="bibr" rid="b30">Karsenty and Wagner, 2002</xref>
###xml 202 207 202 207 <italic>et al</italic>
###xml 196 213 196 213 <xref ref-type="bibr" rid="b8">Boyle <italic>et al</italic>, 2003</xref>
###xml 215 237 215 237 <xref ref-type="bibr" rid="b20">Harada and Rodan, 2003</xref>
###xml 308 329 308 329 <xref ref-type="bibr" rid="b39">Martin and Sims, 2005</xref>
###xml 524 538 524 538 <xref ref-type="bibr" rid="b23">Helfrich, 2003</xref>
###xml 540 565 540 565 <xref ref-type="bibr" rid="b63">Teitelbaum and Ross, 2003</xref>
###xml 572 577 572 577 <italic>et al</italic>
###xml 567 583 567 583 <xref ref-type="bibr" rid="b47">Phan <italic>et al</italic>, 2004</xref>
###xml 585 610 585 610 <xref ref-type="bibr" rid="b16">Ehrlich and Roodman, 2005</xref>
Bone homeostasis is controlled by the interplay between bone-forming osteoblasts and bone-resorbing osteoclasts (Karsenty and Wagner, 2002). The dynamics of bone remodelling is tightly regulated (Boyle et al, 2003; Harada and Rodan, 2003) and is based on intercellular communication between both cell types (Martin and Sims, 2005). Disturbance of the balance between osteoblasts and osteoclasts often results in enhanced bone resorption, usually involving hyperactive osteoclasts and causing focal or generalized bone loss (Helfrich, 2003; Teitelbaum and Ross, 2003; Phan et al, 2004; Ehrlich and Roodman, 2005).
###end p 5
###begin p 6
###xml 215 220 209 214 <italic>et al</italic>
###xml 205 226 199 220 <xref ref-type="bibr" rid="b53">Screpanti <italic>et al</italic>, 1995</xref>
###xml 235 240 229 234 <italic>et al</italic>
###xml 228 246 222 240 <xref ref-type="bibr" rid="b61">Tanaka <italic>et al</italic>, 1995</xref>
###xml 248 258 242 252 <xref ref-type="bibr" rid="b48">Poli, 1998</xref>
###xml 260 286 254 280 <xref ref-type="bibr" rid="b51">Rosen and MacDougald, 2006</xref>
###xml 296 301 290 295 <italic>et al</italic>
###xml 288 307 282 301 <xref ref-type="bibr" rid="b65">Uematsu <italic>et al</italic>, 2007</xref>
###xml 919 939 886 906 <xref ref-type="bibr" rid="b49">Ramji and Foka, 2002</xref>
###xml 941 954 908 921 <xref ref-type="bibr" rid="b27">Johnson, 2005</xref>
###xml 956 968 923 935 <xref ref-type="bibr" rid="b42">Nerlov, 2007</xref>
###xml 1054 1059 1014 1019 <italic>et al</italic>
###xml 1048 1065 1008 1025 <xref ref-type="bibr" rid="b5">Begay <italic>et al</italic>, 2004</xref>
###xml 1094 1099 1054 1059 <italic>et al</italic>
###xml 1085 1105 1045 1065 <xref ref-type="bibr" rid="b43">Pedersen <italic>et al</italic>, 2007</xref>
###xml 1112 1117 1072 1077 <italic>et al</italic>
###xml 1107 1123 1067 1083 <xref ref-type="bibr" rid="b70">Wang <italic>et al</italic>, 2008</xref>
###xml 1148 1153 1108 1113 <italic>et al</italic>
###xml 1142 1159 1102 1119 <xref ref-type="bibr" rid="b75">Zhang <italic>et al</italic>, 2002</xref>
###xml 1167 1172 1127 1132 <italic>et al</italic>
###xml 1161 1178 1121 1138 <xref ref-type="bibr" rid="b24">Hirai <italic>et al</italic>, 2006</xref>
###xml 1209 1234 1169 1194 <xref ref-type="bibr" rid="b1">Akira and Kishimoto, 1992</xref>
###xml 1236 1246 1196 1206 <xref ref-type="bibr" rid="b48">Poli, 1998</xref>
###xml 1353 1373 1303 1323 <xref ref-type="bibr" rid="b49">Ramji and Foka, 2002</xref>
###xml 1375 1388 1325 1338 <xref ref-type="bibr" rid="b27">Johnson, 2005</xref>
###xml 1469 1474 1415 1420 <italic>et al</italic>
###xml 1462 1480 1408 1426 <xref ref-type="bibr" rid="b62">Tanaka <italic>et al</italic>, 1997</xref>
###xml 1482 1508 1428 1454 <xref ref-type="bibr" rid="b58">Sterneck and Johnson, 1998</xref>
The transcription factor CCAAT/enhancer binding protein beta (C/EBPbeta) is involved in the differentiation and function of haematopoietic and mesenchymal cell types, including macrophages and adipocytes (Screpanti et al, 1995; Tanaka et al, 1995; Poli, 1998; Rosen and MacDougald, 2006; Uematsu et al, 2007), cell lineages closely related to bone cells. C/EBPbeta is a member of the family of C/EBP transcription factors (alpha, beta, gamma, delta, epsilon and zeta). C/EBPs have highly conserved basic leucine zipper domains (bZIP) involved in dimerization and DNA binding, and a variable N-terminal region involved in the regulation of gene expression. C/EBPs regulate proliferation and differentiation of many different cell types, including adipocytes, mammary epithelial cells, ovarian luteal cells, keratinocytes, hepatocytes, neuronal cells, intestinal epithelial cells and cells of the haematopoietic lineage (Ramji and Foka, 2002; Johnson, 2005; Nerlov, 2007). The two main members, C/EBPalpha and beta, are required for placentogenesis (Begay et al, 2004), liver functions (Pedersen et al, 2007; Wang et al, 2008), granulopoiesis (Zhang et al, 2002; Hirai et al, 2006) and innate immune functions (Akira and Kishimoto, 1992; Poli, 1998). C/EBPgamma is ubiquitously expressed and expression of C/EBPepsilon is mostly confined to granulocytes (Ramji and Foka, 2002; Johnson, 2005), whereas C/EBPdelta is involved in adipogenesis and neuronal functions (Tanaka et al, 1997; Sterneck and Johnson, 1998).
###end p 6
###begin p 7
###xml 147 148 141 142 <sup>*</sup>
###xml 163 191 157 185 <xref ref-type="bibr" rid="b15">Descombes and Schibler, 1991</xref>
###xml 285 290 279 284 <italic>et al</italic>
###xml 275 296 269 290 <xref ref-type="bibr" rid="b9">Calkhoven <italic>et al</italic>, 2000</xref>
###xml 304 309 298 303 <italic>et al</italic>
###xml 298 315 292 309 <xref ref-type="bibr" rid="b72">Xiong <italic>et al</italic>, 2001</xref>
###xml 566 571 557 562 <italic>et al</italic>
###xml 556 577 547 568 <xref ref-type="bibr" rid="b9">Calkhoven <italic>et al</italic>, 2000</xref>
###xml 585 590 576 581 <italic>et al</italic>
###xml 579 596 570 587 <xref ref-type="bibr" rid="b28">Jundt <italic>et al</italic>, 2005</xref>
###xml 707 734 698 725 <xref ref-type="bibr" rid="b54">Sebastian and Johnson, 2006</xref>
###xml 820 821 811 812 <sup>*</sup>
###xml 960 988 948 976 <xref ref-type="bibr" rid="b35">Kowenz-Leutz and Leutz, 1999</xref>
###xml 1000 1005 988 993 <italic>et al</italic>
###xml 990 1011 978 999 <xref ref-type="bibr" rid="b10">Calkhoven <italic>et al</italic>, 2002</xref>
###xml 1013 1025 1001 1013 <xref ref-type="bibr" rid="b42">Nerlov, 2007</xref>
C/EBPbeta is an intronless gene, yet different isoforms are expressed with successively truncated N-termini. The C/EBPbeta isoforms were termed LAP*, LAP and LIP (Descombes and Schibler, 1991) and arise by alternative translation initiation at distinct in frame start sites (Calkhoven et al, 2000; Xiong et al, 2001). Alternative translation initiation and thus C/EBPbeta isoform production is regulated through the mammalian target of rapamycin (mTOR) pathway: activation of mTOR enhances generation of LIP and inhibition of mTOR enhances LAP production (Calkhoven et al, 2000; Jundt et al, 2005). The truncated and dominant inhibitory isoform (LIP) may also arise by partial proteolysis of long isoforms (Sebastian and Johnson, 2006). All isoforms contain the C-terminal bZIP domain. In addition, the long isoforms LAP* and LAP contain N-terminal transactivation and chromatin remodelling domains. The C/EBPbeta isoform ratio is thought to direct cell fate (Kowenz-Leutz and Leutz, 1999; Calkhoven et al, 2002; Nerlov, 2007).
###end p 7
###begin p 8
###xml 128 136 125 133 <italic>in vitro</italic>
###xml 148 153 145 150 <italic>et al</italic>
###xml 138 159 135 156 <xref ref-type="bibr" rid="b19">Gutierrez <italic>et al</italic>, 2002</xref>
###xml 166 171 163 168 <italic>et al</italic>
###xml 161 177 158 174 <xref ref-type="bibr" rid="b22">Hata <italic>et al</italic>, 2005</xref>
###xml 188 193 185 190 <italic>et al</italic>
###xml 179 199 176 196 <xref ref-type="bibr" rid="b69">Villagra <italic>et al</italic>, 2006</xref>
###xml 397 402 391 396 <italic>et al</italic>
###xml 388 408 382 402 <xref ref-type="bibr" rid="b64">Tominaga <italic>et al</italic>, 2008</xref>
###xml 548 553 542 547 <italic>et al</italic>
###xml 539 559 533 553 <xref ref-type="bibr" rid="b21">Harrison <italic>et al</italic>, 2005</xref>
###xml 422 437 <span type="species:ncbi:10090">transgenic mice</span>
It has been shown that over-expression of full-length C/EBPbeta or of its short LIP isoform supports osteoblast differentiation in vitro (Gutierrez et al, 2002; Hata et al, 2005; Villagra et al, 2006). In agreement with this, a recent study showed that absence of C/EBPbeta at embryonic and neonatal stages results in delayed bone formation and suppression of osteoblast differentiation (Tominaga et al, 2008). Similarly, transgenic mice expressing only the short LIP isoform in the osteoblast lineage displayed attenuated bone formation (Harrison et al, 2005). Although the action of C/EBPbeta in osteoblasts has been addressed in several studies, the general function of C/EBPbeta in bone homeostasis, including its potential role in osteoclasts, remains to be examined.
###end p 8
###begin p 9
###xml 66 71 66 71 <italic>c/ebp</italic>
###xml 92 97 89 94 <italic>et al</italic>
###xml 83 103 80 100 <xref ref-type="bibr" rid="b59">Sterneck <italic>et al</italic>, 1997</xref>
###xml 182 185 179 182 <italic>LIP</italic>
###xml 196 199 193 196 <italic>L/L</italic>
###xml 651 654 639 642 <italic>L/L</italic>
###xml 763 768 751 756 <italic>et al</italic>
###xml 759 774 747 762 <xref ref-type="bibr" rid="b32">Kim <italic>et al</italic>, 2007</xref>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
###xml 610 614 <span type="species:ncbi:10090">mice</span>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
Here, we have used genetically altered mice, either deficient for c/ebpbeta (-/-) (Sterneck et al, 1997), or expressing only the truncated LIP isoform from its native genetic locus (LIP knock-in; L/L), to examine C/EBPbeta functions in bone tissue. Osteogenesis and osteoclastogenesis were both affected in the absence of C/EBPbeta or in the presence of LIP only. Importantly, the translationally controlled ratio between LAP and LIP isoforms strongly affected osteoclastogenesis. Rapamycin, an inhibitor of mTOR, enhanced LAP expression and constrained differentiation of osteoclasts from wild-type (WT, +/+) mice but not from C/EBPbeta deficient or L/L mice. Expression of LAP-induced expression of MafB, a negative regulator of osteoclast differentiation (Kim et al, 2007), whereas LIP inhibited expression of MafB and enhanced osteoclastogenesis. Our data suggest that signalling through mTOR affects the C/EBPbeta isoform ratio that in turn regulates MafB expression as a major factor controlling osteoclast differentiation and bone homeostasis. Our results raise the possibility that dysregulated translational control of C/EBPbeta isoform expression might be involved in bone diseases.
###end p 9
###begin title 10
Results
###end title 10
###begin title 11
###xml 19 23 19 20 <italic>&#946;</italic>
Expression of C/EBPbeta in bone cells
###end title 11
###begin p 12
###xml 247 256 238 247 <xref ref-type="fig" rid="f1">Figure 1A</xref>
###xml 278 287 269 278 <xref ref-type="fig" rid="f1">Figure 1B</xref>
###xml 332 341 323 332 <xref ref-type="fig" rid="f1">Figure 1B</xref>
###xml 365 375 356 366 <xref ref-type="fig" rid="f1">Figure 1C,</xref>
###xml 482 491 470 479 <xref ref-type="fig" rid="f1">Figure 1D</xref>
###xml 726 735 705 714 <xref ref-type="fig" rid="f1">Figure 1E</xref>
To examine whether C/EBPbeta could have a function in bone homeostasis, expression of C/EBPbeta was analysed in the different bone cell types. Immunohistochemistry of bone tissue revealed C/EBPbeta protein expression in growth plate chondrocytes (Figure 1A) and in osteoblasts (Figure 1B and C, arrowheads), but not in osteoclasts (Figure 1B, arrow) or osteocytes (Figure 1C, arrows). During osteoblast differentiation, expression of all three C/EBPbeta protein isoforms increased (Figure 1D). Monocytic precursors derived from the bone marrow expressed all three C/EBPbeta protein isoforms and C/EBPbeta expression vanished during differentiation into osteoclasts and no C/EBPbeta protein was detected in mature osteoclasts (Figure 1E). Thus, C/EBPbeta protein expression is reciprocally regulated during differentiation of the two cell lineages controlling bone homeostasis.
###end p 12
###begin title 13
###xml 27 31 27 28 <italic>&#946;</italic>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
Affected bone mass in c/ebpbeta mutant mice
###end title 13
###begin p 14
###xml 244 247 235 238 <italic>LIP</italic>
###xml 308 311 296 299 <italic>L/L</italic>
###xml 318 333 306 321 <xref ref-type="fig" rid="f2">Figure 2A and B</xref>
###xml 360 365 348 353 <italic>c/ebp</italic>
###xml 396 401 381 386 <italic>et al</italic>
###xml 387 407 372 392 <xref ref-type="bibr" rid="b59">Sterneck <italic>et al</italic>, 1997</xref>
###xml 499 502 484 487 <italic>LIP</italic>
###xml 514 517 499 502 <italic>L/L</italic>
###xml 524 533 509 518 <xref ref-type="fig" rid="f2">Figure 2C</xref>
###xml 536 539 521 524 <italic>L/L</italic>
###xml 599 600 584 585 <italic>n</italic>
###xml 765 768 750 753 <italic>L/L</italic>
###xml 775 780 760 765 <italic>c/ebp</italic>
###xml 784 787 766 769 <sup>&#8722;/&#8722;</sup>
###xml 931 936 913 918 <italic>et al</italic>
###xml 924 942 906 924 <xref ref-type="bibr" rid="b61">Tanaka <italic>et al</italic>, 1995</xref>
###xml 953 958 935 940 <italic>et al</italic>
###xml 944 964 926 946 <xref ref-type="bibr" rid="b59">Sterneck <italic>et al</italic>, 1997</xref>
###xml 219 223 <span type="species:ncbi:10090">mice</span>
###xml 312 316 <span type="species:ncbi:10090">mice</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
###xml 466 470 <span type="species:ncbi:10090">mice</span>
###xml 518 522 <span type="species:ncbi:10090">mice</span>
###xml 540 544 <span type="species:ncbi:10090">mice</span>
###xml 769 773 <span type="species:ncbi:10090">mice</span>
###xml 788 792 <span type="species:ncbi:10090">mice</span>
###xml 848 852 <span type="species:ncbi:10090">mice</span>
Reciprocal expression of C/EBPbeta in osteoblasts and osteoclasts suggested cell-type specific functions of C/EBPbeta and its isoforms in bone tissue. To characterize the function of C/EBPbeta and its isoforms in bone, mice expressing only the LIP isoform from the endogenous C/EBPbeta locus were generated (L/L mice; Figure 2A and B) and compared with WT and c/ebpbeta knock-out (-/-) (Sterneck et al, 1997) mice. Analysis of liver protein extracts from 8-week-old mice confirmed expression of the LIP isoform in L/L mice (Figure 2C). L/L mice were born at a slightly reduced Mendelian ratio (18%, n=324). Peripheral blood cell counts, spleen and liver weights and their histological parameters were comparable with WT (+/+) animals (data not shown). Similarly to L/L mice, c/ebpbeta-/- mice are born at a reduced Mendelian ratio. However, viable mice developed normally until at least 10 weeks of age (our observation and Tanaka et al, 1995; Sterneck et al, 1997).
###end p 14
###begin p 15
###xml 43 46 43 46 <italic>L/L</italic>
###xml 48 53 48 53 <italic>c/ebp</italic>
###xml 84 89 81 86 <italic>et al</italic>
###xml 75 95 72 92 <xref ref-type="bibr" rid="b59">Sterneck <italic>et al</italic>, 1997</xref>
###xml 138 143 135 140 <italic>C/ebp</italic>
###xml 147 150 141 144 <sup>&#8722;/&#8722;</sup>
###xml 240 245 234 239 <italic>c/ebp</italic>
###xml 351 356 342 347 <italic>c/ebp</italic>
###xml 360 363 348 351 <sup>&#8722;/&#8722;</sup>
###xml 486 495 474 483 <xref ref-type="fig" rid="f3">Figure 3A</xref>
###xml 497 518 485 506 <xref ref-type="supplementary-material" rid="S1">Supplementary Table 1</xref>
###xml 534 537 522 525 <italic>L/L</italic>
###xml 665 674 653 662 <xref ref-type="fig" rid="f3">Figure 3A</xref>
###xml 676 697 664 685 <xref ref-type="supplementary-material" rid="S1">Supplementary Table 1</xref>
###xml 762 767 750 755 <italic>c/ebp</italic>
###xml 771 774 756 759 <sup>&#8722;/&#8722;</sup>
###xml 781 784 766 769 <italic>L/L</italic>
###xml 791 812 776 797 <xref ref-type="supplementary-material" rid="S1">Supplementary Table 1</xref>
###xml 919 940 904 925 <xref ref-type="supplementary-material" rid="S1">Supplementary Table 1</xref>
###xml 1108 1111 1093 1096 <italic>L/L</italic>
###xml 1243 1248 1228 1233 <italic>c/ebp</italic>
###xml 1280 1283 1262 1265 <italic>LIP</italic>
###xml 1364 1367 1346 1349 <italic>LIP</italic>
###xml 110 114 <span type="species:ncbi:10090">mice</span>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
###xml 538 542 <span type="species:ncbi:10090">mice</span>
###xml 602 606 <span type="species:ncbi:10090">mice</span>
###xml 785 789 <span type="species:ncbi:10090">mice</span>
###xml 1112 1116 <span type="species:ncbi:10090">mice</span>
###xml 1225 1229 <span type="species:ncbi:10090">mice</span>
###xml 1266 1270 <span type="species:ncbi:10090">mice</span>
###xml 1297 1301 <span type="species:ncbi:10090">mice</span>
###xml 1368 1372 <span type="species:ncbi:10090">mice</span>
Bone development was analysed by comparing L/L, c/ebpbeta knock-out (-/-) (Sterneck et al, 1997) and WT (+/+) mice at the age of 8 weeks. C/ebpbeta-/- animals displayed reduced bone length that was restored by replacement of the endogenous c/ebpbeta gene with the LIP isoform (data not shown). Histomorphometric analyses of the long bones showed that c/ebpbeta-/- mice have a 1.6-fold diminished bone volume, characterized by a reduction of the number and thickness of bone trabeculae (Figure 3A; Supplementary Table 1). In contrast, L/L mice had a 1.7-fold increased bone volume in comparison with WT mice, displaying increased number and thickness of trabeculae (Figure 3A; Supplementary Table 1). However, the number of osteoblasts was not affected in either c/ebpbeta-/- or in L/L mice (Supplementary Table 1). These effects on bone tissue were observed at several sites in the skeleton (long bones and vertebrae) (Supplementary Table 1 and data not shown). The observed bone phenotypes were already apparent at birth in both mutants and persisted with age (data not shown). The increased bone volume in L/L mice did not evoke extramedullary haematopoiesis (data not shown). No difference in bone volume compared with WT mice was found in c/ebpbeta heterozygous mice, whereas LIP heterozygous mice displayed an intermediate phenotype between WT and homozygous LIP mice (data not shown). Both heterozygotes were therefore not further analysed.
###end p 15
###begin p 16
###xml 103 108 103 108 <italic>c/ebp</italic>
###xml 112 115 109 112 <sup>&#8722;/&#8722;</sup>
###xml 253 256 250 253 <italic>L/L</italic>
###xml 263 272 260 269 <xref ref-type="fig" rid="f3">Figure 3B</xref>
###xml 312 317 309 314 <italic>c/ebp</italic>
###xml 321 324 315 318 <sup>&#8722;/&#8722;</sup>
###xml 329 332 323 326 <italic>L/L</italic>
###xml 464 469 458 463 <italic>c/ebp</italic>
###xml 473 476 464 467 <sup>&#8722;/&#8722;</sup>
###xml 481 484 472 475 <italic>L/L</italic>
###xml 514 523 505 514 <xref ref-type="fig" rid="f3">Figure 3C</xref>
###xml 525 553 516 544 <xref ref-type="supplementary-material" rid="S1">Supplementary Tables 1 and 2</xref>
###xml 685 713 676 704 <xref ref-type="supplementary-material" rid="S1">Supplementary Tables 1 and 2</xref>
###xml 844 853 835 844 <xref ref-type="fig" rid="f3">Figure 3C</xref>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
###xml 257 261 <span type="species:ncbi:10090">mice</span>
###xml 333 337 <span type="species:ncbi:10090">mice</span>
###xml 358 362 <span type="species:ncbi:10090">mice</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
###xml 508 512 <span type="species:ncbi:10090">mice</span>
The rate of bone formation was assessed in animals by double calcein labelling. In comparison with WT, c/ebpbeta-/- mice displayed decreased mineral apposition and bone formation rate, whereas mineral apposition and bone formation rate was increased in L/L mice (Figure 3B). Bone resorption was enhanced in both c/ebpbeta-/- and L/L mice as compared with WT mice. Histomorphometric analyses revealed larger osteoclasts (TRACP-positive cells, red staining) in both c/ebpbeta-/- and L/L mice, compared with WT mice (Figure 3C; Supplementary Tables 1 and 2). Although the total number of osteoclasts was not affected, an increase in the number of multinucleated osteoclasts was observed (Supplementary Tables 1 and 2). These enlarged osteoclasts caused enhanced bone resorption, as shown by increased urinary excretion of deoxypyridinoline (DPD) (Figure 3C). Thus, bone formation was decreased in the absence of C/EBPbeta and osteoclastogenesis was enhanced, both contributing to the observed osteopenia. Expression of LIP, similarly to the absence of C/EBPbeta, also enhanced osteoclastogenesis, that was however, surpassed by enhanced bone formation.
###end p 16
###begin title 17
LIP promotes osteoblast differentiation
###end title 17
###begin p 18
###xml 44 47 44 47 <italic>L/L</italic>
###xml 221 230 221 230 <xref ref-type="fig" rid="f4">Figure 4A</xref>
###xml 290 299 290 299 <xref ref-type="fig" rid="f4">Figure 4B</xref>
###xml 463 485 463 485 <xref ref-type="supplementary-material" rid="S1">Supplementary Table 3A</xref>
###xml 592 614 592 614 <xref ref-type="supplementary-material" rid="S1">Supplementary Table 3A</xref>
###xml 785 807 785 807 <xref ref-type="supplementary-material" rid="S1">Supplementary Table 3B</xref>
###xml 915 920 915 920 <italic>et al</italic>
###xml 910 926 910 926 <xref ref-type="bibr" rid="b22">Hata <italic>et al</italic>, 2005</xref>
###xml 1110 1113 1110 1113 <italic>L/L</italic>
###xml 1192 1195 1192 1195 <italic>L/L</italic>
###xml 1237 1242 1237 1242 <italic>c/ebp</italic>
###xml 1246 1249 1243 1246 <sup>&#8722;/&#8722;</sup>
###xml 1354 1369 1351 1366 <xref ref-type="fig" rid="f4">Figure 4A and B</xref>
###xml 1371 1392 1368 1389 <xref ref-type="supplementary-material" rid="S1">Supplementary Table 3</xref>
###xml 1483 1488 1480 1485 <italic>c/ebp</italic>
###xml 1492 1495 1486 1489 <sup>&#8722;/&#8722;</sup>
###xml 1502 1511 1496 1505 <xref ref-type="fig" rid="f3">Figure 3A</xref>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 1196 1200 <span type="species:ncbi:10090">mice</span>
###xml 1496 1500 <span type="species:ncbi:10090">mice</span>
Osteoblasts derived from calvarial bones of L/L mice displayed enhanced differentiation (as also observed for long bones derived osteoblasts, data not shown), as revealed by increased alkaline phosphatase (ALP) activity (Figure 4A), mineralization of bone nodules (alizarin red staining in Figure 4B) and increased expression of early and late osteoblast differentiation markers, such as osteopontin, ALP, bone sialoprotein, collagen type I and osteocalcin (OC) (Supplementary Table 3A). Moreover, expression of the essential osteogenic transcription factors Runx2 and osterix was increased (Supplementary Table 3A), whereas no differences in the expression of several of the Wnt components (Lef1, Tcf1 and Tcf3), or of the AP-1 family members Fra1, Fra2, c-Fos and JunD was observed (Supplementary Table 3B). LIP has been shown earlier to act as a co-activator of Runx2, promoting osteoblast differentiation (Hata et al, 2005), which, together with the enhanced Runx2 and Osterix expression may contribute to enhanced osteogenesis. These data suggest a cell autonomously enhanced differentiation potential of L/L osteoblasts that may underlie the increase in bone formation rate observed in L/L mice. However, differentiation of WT and c/ebpbeta-/- osteoblasts in tissue culture, either derived from calvaria or long bones (data not shown) was similar (Figure 4A and B; Supplementary Table 3), suggesting microenvironmental cues might also be involved in the observed osteopenia in c/ebpbeta-/- mice (Figure 3A).
###end p 18
###begin title 19
###xml 44 48 44 45 <italic>&#946;</italic>
###xml 48 51 45 48 <sup>&#8722;/&#8722;</sup>
Enhanced osteoclast differentiation of c/ebpbeta-/- and L/L cells
###end title 19
###begin p 20
###xml 160 165 156 161 <italic>et al</italic>
###xml 152 171 148 167 <xref ref-type="bibr" rid="b57">Simonet <italic>et al</italic>, 1997</xref>
###xml 179 184 175 180 <italic>et al</italic>
###xml 173 190 169 186 <xref ref-type="bibr" rid="b8">Boyle <italic>et al</italic>, 2003</xref>
###xml 192 217 188 213 <xref ref-type="bibr" rid="b63">Teitelbaum and Ross, 2003</xref>
###xml 237 242 233 238 <italic>c/ebp</italic>
###xml 246 249 239 242 <sup>&#8722;/&#8722;</sup>
###xml 254 257 247 250 <italic>L/L</italic>
###xml 390 399 379 388 <xref ref-type="fig" rid="f5">Figure 5A</xref>
###xml 518 527 504 513 <xref ref-type="fig" rid="f5">Figure 5B</xref>
###xml 770 779 750 759 <xref ref-type="fig" rid="f5">Figure 5C</xref>
###xml 870 875 850 855 <italic>c/ebp</italic>
###xml 879 882 856 859 <sup>&#8722;/&#8722;</sup>
###xml 887 890 864 867 <italic>L/L</italic>
###xml 897 906 874 883 <xref ref-type="fig" rid="f3">Figure 3C</xref>
###xml 891 895 <span type="species:ncbi:10090">mice</span>
Osteoblasts control the differentiation and activity of osteoclasts by release of signalling molecules such as TNFalpha, RANK-L and its antagonist OPG (Simonet et al, 1997; Boyle et al, 2003; Teitelbaum and Ross, 2003). Analysis of both c/ebpbeta-/- and L/L primary osteoblasts showed diminished expression of the pro-osteoclastogenic factors RANK-L and TNFalpha and of the antagonist OPG (Figure 5A). Co-culturing C/EBPbeta mutant osteoblasts with WT bone marrow cells reduced osteoclast differentiation of WT cells (Figure 5B), in accordance with decreased expression of osteoclastogenic factors by the mutant osteoblasts and co-culturing WT osteoblasts with C/EBPbeta mutant bone marrow cells showed enhanced osteoclast differentiation of the C/EBPbeta mutant cells (Figure 5C). Thus, paracrine effects do not explain the enhanced osteoclastogenesis observed in both c/ebpbeta-/- and L/L mice (Figure 3C) and suggest a cell autonomous mechanism.
###end p 20
###begin p 21
###xml 12 21 12 21 <xref ref-type="fig" rid="f6">Figure 6A</xref>
###xml 54 59 54 59 <italic>c/ebp</italic>
###xml 63 66 60 63 <sup>&#8722;/&#8722;</sup>
###xml 76 79 73 76 <italic>L/L</italic>
###xml 314 319 311 316 <italic>c/ebp</italic>
###xml 323 326 317 320 <sup>&#8722;/&#8722;</sup>
###xml 331 334 325 328 <italic>L/L</italic>
###xml 362 363 356 357 <italic>P</italic>
###xml 529 538 523 532 <xref ref-type="fig" rid="f6">Figure 6B</xref>
###xml 807 812 801 806 <italic>et al</italic>
###xml 802 818 796 812 <xref ref-type="bibr" rid="b73">Yagi <italic>et al</italic>, 2005</xref>
###xml 821 830 815 824 <xref ref-type="fig" rid="f6">Figure 6C</xref>
###xml 1259 1268 1250 1259 <xref ref-type="fig" rid="f3">Figure 3C</xref>
###xml 1270 1291 1261 1282 <xref ref-type="supplementary-material" rid="S1">Supplementary Table 2</xref>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
As shown in Figure 6A, bone marrow cell cultures from c/ebpbeta-/- and from L/L mice generated more and larger osteoclasts (containing more nuclei/TRACP-positive cell) compared with WT cells after 6 days of treatment with M-CSF and RANK-L. Only 10% of WT osteoclasts contained >5 nuclei/cell, versus 42 and 51% in c/ebpbeta-/- and L/L osteoclasts, respectively (P<0.001 compared with WT). The exacerbated osteoclast formation was accompanied by enhanced osteoclast activity, as shown by increased bone resorption on bone slices (Figure 6B), increased expression of the osteoclastic differentiation markers, TRACP, cathepsin K (CathK), calcitonin receptor (CTR), OSCAR (osteoclast-associated receptor) and of the osteoclastic cell fusion marker DC-STAMP (dendritic cell-specific transmembrane protein) (Yagi et al, 2005) (Figure 6C). Expression of RANK (RANK-L receptor) was not affected and expression of c-Fms (M-CSF receptor) was only slightly elevated in osteoclasts of both mutants (data not shown), excluding elevated cytokine receptor levels as a cause of enhanced osteoclastogenesis of mutant cells. These data are consistent with a cell intrinsic defect of osteoclasts in C/EBPbeta mutants and are in accordance with the observations made in animals (Figure 3C; Supplementary Table 2).
###end p 21
###begin p 22
###xml 96 119 96 119 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 1A</xref>
###xml 256 261 256 261 <italic>et al</italic>
###xml 241 267 241 267 <xref ref-type="bibr" rid="b68">van der Eerden <italic>et al</italic>, 2005</xref>
###xml 337 342 337 342 <italic>c/ebp</italic>
###xml 346 349 343 346 <sup>&#8722;/&#8722;</sup>
###xml 354 357 351 354 <italic>L/L</italic>
###xml 458 487 455 484 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 1A and B</xref>
###xml 690 695 687 692 <italic>c/ebp</italic>
###xml 699 702 693 696 <sup>&#8722;/&#8722;</sup>
###xml 707 710 701 704 <italic>L/L</italic>
###xml 913 922 904 913 <xref ref-type="fig" rid="f6">Figure 6D</xref>
Cultures of osteoclast precursors exhibited similar numbers of osteoclasts 1 day after seeding (Supplementary Figure 1A; both mononuclear and multi-nucleated TRACP-positive cells), reflecting a comparable pool of osteoclast precursor cells (van der Eerden et al, 2005) in all genotypes tested. However, on day 2 of differentiation, both c/ebpbeta-/- and L/L bone marrow cells generated significantly more mononuclear and multinucleated TRACP-positive cells (Supplementary Figure 1A and B), which was accompanied by an increased expression of the osteoclastic differentiation markers, TRACP, CathK, CTR and OSCAR (data not shown). These data indicate that the enhanced osteoclastogenesis of c/ebpbeta-/- and L/L cells is initiated at early stages of osteoclast differentiation. In agreement with this, an increase in cleaved-caspase 3 expression was observed in C/EBPbeta mutant but not in WT osteoclast cultures (Figure 6D) and likewise, apoptotic cells were present in mutant cultures but not in WT cultures after 6 days (data not shown). These data signify that the presence of enlarged osteoclasts is not caused by a diminished or delayed apoptosis of C/EBPbeta mutant cells, but by accelerated differentiation and enhanced cell fusion.
###end p 22
###begin p 23
###xml 209 232 209 232 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 1C</xref>
###xml 430 453 423 446 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 1C</xref>
###xml 538 543 527 532 <italic>et al</italic>
###xml 534 549 523 538 <xref ref-type="bibr" rid="b37">Lam <italic>et al</italic>, 2000</xref>
###xml 610 615 599 604 <italic>c/ebp</italic>
###xml 619 622 605 608 <sup>&#8722;/&#8722;</sup>
###xml 627 630 613 616 <italic>L/L</italic>
###xml 694 699 680 685 <italic>c/ebp</italic>
###xml 703 706 686 689 <sup>&#8722;/&#8722;</sup>
###xml 711 714 694 697 <italic>L/L</italic>
###xml 775 798 754 777 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 2A</xref>
###xml 907 912 874 879 <italic>et al</italic>
###xml 900 918 867 885 <xref ref-type="bibr" rid="b11">Childs <italic>et al</italic>, 2001</xref>
###xml 971 994 938 961 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 2B</xref>
###xml 1084 1107 1051 1074 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 2A</xref>
###xml 722 726 <span type="species:ncbi:10090">mice</span>
Accelerated osteoclast differentiation was accompanied by increased expression of the osteoclastic transcription factor NFATc1 at early stages in differentiation, whereas expression of c-Fos was not affected (Supplementary Figure 1C). In addition, expression of the osteoclastic cell fusion genes ATP6v0d2 and DC-STAMP, as well as of TNFalpha was increased early in osteoclast differentiation in the C/EBPbeta mutant osteoclasts (Supplementary Figure 1C). TNFalpha has been shown to enhance RANK-L-induced osteoclast differentiation (Lam et al, 2000) and its contribution to the enhanced osteoclastogenesis in c/ebpbeta-/- and L/L cells was studied therefore in more detail. Cell cultures from c/ebpbeta-/- and L/L mutant mice displayed elevated TNFalpha protein expression (Supplementary Figure 2A) and neutralization of TNFalpha by the TNFalpha antagonist Etanercept (a decoy receptor of TNFalpha (Childs et al, 2001)) restrained excessive cell fusion in both mutants (Supplementary Figure 2B). No effect of Etanercept on the formation of osteoclasts from WT cultures was observed (Supplementary Figure 2A). Thus, C/EBPbeta defects augment TNFalpha expression, which contributes to the exacerbated osteoclastogenesis.
###end p 23
###begin title 24
###xml 52 56 52 53 <italic>&#946;</italic>
mTOR regulates osteoclastogenesis by switching C/EBPbeta isoforms
###end title 24
###begin p 25
###xml 154 159 151 156 <italic>et al</italic>
###xml 144 165 141 162 <xref ref-type="bibr" rid="b10">Calkhoven <italic>et al</italic>, 2002</xref>
###xml 173 178 170 175 <italic>et al</italic>
###xml 167 184 164 181 <xref ref-type="bibr" rid="b28">Jundt <italic>et al</italic>, 2005</xref>
###xml 312 321 306 315 <xref ref-type="fig" rid="f7">Figure 7A</xref>
###xml 410 419 404 413 <xref ref-type="fig" rid="f7">Figure 7A</xref>
###xml 525 530 519 524 <italic>c/ebp</italic>
###xml 534 537 525 528 <sup>&#8722;/&#8722;</sup>
###xml 542 545 533 536 <italic>L/L</italic>
###xml 611 620 602 611 <xref ref-type="fig" rid="f7">Figure 7A</xref>
###xml 796 805 787 796 <xref ref-type="fig" rid="f7">Figure 7B</xref>
###xml 932 937 920 925 <italic>c/ebp</italic>
###xml 941 944 926 929 <sup>&#8722;/&#8722;</sup>
###xml 949 952 934 937 <italic>L/L</italic>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
###xml 546 550 <span type="species:ncbi:10090">mice</span>
###xml 953 957 <span type="species:ncbi:10090">mice</span>
Alternative translation initiation of C/EBPbeta isoforms can be shifted towards LAP expression by inhibition of mTOR signalling with rapamycin (Calkhoven et al, 2002; Jundt et al, 2005). Bone marrow derived osteoclasts from WT or C/EBPbeta mutant mice were treated with rapamycin and stained for TRACP-activity (Figure 7A). Rapamycin completely blocked formation of multi-nucleated osteoclasts in WT cultures (Figure 7A). In contrast, osteoclast formation was only slightly affected by rapamycin treatment in cells from both c/ebpbeta-/- and L/L mice (which do not express or cannot switch to the LAP isoform) (Figure 7A). Protein expression analysis confirmed that rapamycin treatment caused a shift towards LAP expression in WT cultures (approximately five-fold change of the LAP to LIP ratio; Figure 7B). These data show that the inhibition of osteoclastogenesis by rapamycin depends on C/EBPbeta LAP, as cells derived from both c/ebpbeta-/- and L/L mice are almost unresponsive. We conclude that mTOR adjusts the expression of C/EBPbeta isoforms that in turn differentially control osteoclastogenesis.
###end p 25
###begin p 26
###xml 77 86 77 86 <xref ref-type="fig" rid="f7">Figure 7D</xref>
###xml 180 189 177 186 <xref ref-type="fig" rid="f7">Figure 7C</xref>
###xml 446 455 443 452 <xref ref-type="fig" rid="f7">Figure 7C</xref>
###xml 545 554 542 551 <xref ref-type="fig" rid="f7">Figure 7C</xref>
The LAP and LIP isoforms were expressed in the RAW264.7 monocytic cell line (Figure 7D) to examine whether C/EBPbeta isoforms differentially affect osteoclastogenesis. As shown in Figure 7C, control cells transfected with EGFP differentiated into multi-nucleated osteoclasts in the presence of RANK-L. Ectopic expression of LIP strongly enhanced osteoclastogenesis. Exceptionally large osteoclasts were formed, 40% of which contained >50 nuclei (Figure 7C). In contrast, ectopic expression of LAP almost entirely abolished osteoclast formation (Figure 7C). Most cells remained mononuclear and TRACP-negative and only few, predominantly small TRACP-positive osteoclasts (containing 3-5 nuclei/cell) were present. These data show that the LAP isoform of C/EBPbeta restricts osteoclastogenesis and the LIP isoform enhances osteoclastogenesis.
###end p 26
###begin title 27
###xml 5 9 5 6 <italic>&#946;</italic>
C/EBPbeta isoforms regulate osteoclastogenesis through MafB expression
###end title 27
###begin p 28
###xml 630 639 627 636 <xref ref-type="fig" rid="f8">Figure 8A</xref>
Gene expression profiling was performed to determine possible common genetic targets of C/EBPbeta or rapamycin involved in osteoclastogenesis. A total number of 985 genes were differentially expressed upon LAP expression in RAW264.7 cells under osteoclastic differentiation conditions. Similarly, 490 genes were differentially regulated by rapamycin under similar conditions. Interestingly, comparison of LAP and rapamycin-induced gene expression profiles revealed that 39% of the genes were co-regulated (of the 490 differentially expressed genes following rapamycin treatment, 189 genes were shared with the LAP-induced genes) (Figure 8A). The extensive overlap in gene regulation further support the notion of C/EBPbeta as an important target of rapamycin in osteoclast differentiation.
###end p 28
###begin p 29
###xml 260 265 260 265 <italic>et al</italic>
###xml 256 271 256 271 <xref ref-type="bibr" rid="b32">Kim <italic>et al</italic>, 2007</xref>
###xml 342 351 342 351 <xref ref-type="fig" rid="f8">Figure 8B</xref>
###xml 652 661 649 658 <xref ref-type="fig" rid="f8">Figure 8B</xref>
###xml 839 844 833 838 <italic>c/ebp</italic>
###xml 848 851 839 842 <sup>&#8722;/&#8722;</sup>
###xml 856 859 847 850 <italic>L/L</italic>
###xml 985 994 976 985 <xref ref-type="fig" rid="f8">Figure 8C</xref>
Among the LAP and rapamycin activated genes, MafB stands out (66-fold and 7.4-fold upregulated by LAP and rapamycin treatment, respectively). MafB is a bZIP transcription factor, recently suggested to be a negative regulator of osteoclast differentiation (Kim et al, 2007). Rapamycin treatment of WT osteoclasts increased expression of MafB (Figure 8B) and decreased expression of various osteoclastic markers (data not shown), confirming the profiling data. In the C/EBPbeta mutant osteoclasts that are unresponsive to rapamycin treatment and pursue unrestricted osteoclastogenesis, MafB expression remains low and unaffected after 2 days of culture (Figure 8B). In agreement with this, rapamycin did not affect increased expression of NFATc1, ATP6v0d2 or DC-STAMP in C/EBPbeta mutant osteoclasts (data not shown). In the absence of LAP (c/ebpbeta-/- and L/L osteoclasts), MafB expression even further decreases during osteoclast differentiation compared with WT on day 6 of culture (Figure 8C).
###end p 29
###begin p 30
###xml 65 70 65 70 <italic>et al</italic>
###xml 59 76 59 76 <xref ref-type="bibr" rid="b25">Huang <italic>et al</italic>, 2000</xref>
###xml 203 212 203 212 <xref ref-type="fig" rid="f8">Figure 8D</xref>
###xml 386 395 386 395 <xref ref-type="fig" rid="f8">Figure 8E</xref>
###xml 865 874 853 862 <xref ref-type="fig" rid="f8">Figure 8F</xref>
###xml 1070 1079 1055 1064 <xref ref-type="fig" rid="f8">Figure 8F</xref>
###xml 745 750 <span type="species:ncbi:10090">mouse</span>
The MafB promoter contains a potential C/EBP binding site (Huang et al, 2000) and LAP expression resulted in increased MafB promoter activity, whereas LIP repressed MafB promoter driven transactivation (Figure 8D). Treatment of RAW264.7 cells (under osteoclastic differentiation conditions) with rapamycin, similarly to LAP expression, resulted in transactivation of the MafB promoter (Figure 8E). These data suggest that the LAP isoform of C/EBPbeta inhibits osteoclastogenesis by increasing MafB expression and that absence of the long C/EBPbeta isoforms or presence of LIP opposes MafB expression, resulting in enhanced osteoclast differentiation. To examine these possibilities, gene reporter studies were carried out in C/EBPbeta-deficient mouse embryonic fibroblasts (MEFs). In the absence of C/EBPbeta, the MafB promoter could not be activated by rapamycin (Figure 8F); however, complementation with full-length C/EBPbeta (WT, a construct that contains the upstream open reading frame (uORF)) activated the MafB promoter, which was further enhanced by rapamycin (Figure 8F).
###end p 30
###begin p 31
###xml 372 387 369 384 <xref ref-type="fig" rid="f8">Figure 8G and H</xref>
We conclude that rapamycin mediated mTOR inhibition that switches C/EBPbeta expression towards the LAP isoform, upregulates MafB which then in turn inhibits osteoclastogenesis. In support of this idea, down-regulation of MafB expression by interferring RNA overruled rapamycin treatment whereas control small hairpin RNA (shRNA) constructs did not affect differentiation (Figure 8G and H).
###end p 31
###begin p 32
###xml 380 385 374 379 <italic>et al</italic>
###xml 376 391 370 385 <xref ref-type="bibr" rid="b32">Kim <italic>et al</italic>, 2007</xref>
###xml 457 462 447 452 <italic>et al</italic>
###xml 453 468 443 458 <xref ref-type="bibr" rid="b33">Kim <italic>et al</italic>, 2008</xref>
###xml 471 479 461 469 <xref ref-type="fig" rid="f9">Figure 9</xref>
Altogether these data show that C/EBPbeta mediates the inhibitory effect of rapamycin on osteoclast differentiation, by regulating MafB. Rapamycin induces the production of the LAP isoform of C/EBPbeta and LAP induces the expression of MafB, which subsequently inhibits osteoclast differentiation by negatively regulating osteoclastic transcription factors, including NFATc1 (Kim et al, 2007) and its downstream targets DC-STAMP, ATP6v0d2 and TNFalpha (Kim et al, 2008) (Figure 9).
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 406 407 397 398 <italic>L</italic>
###xml 408 409 399 400 <italic>L</italic>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 366 370 <span type="species:ncbi:10090">mice</span>
###xml 479 483 <span type="species:ncbi:10090">mice</span>
Here, we show that isoforms of the transcription factor CCAAT/enhancer binding protein (C/EBP) beta and its alternative translational initiation are critical in bone formation and resorption. We describe two complex novel bone phenotypes in animals that either lack all C/EBPbeta isoforms or that express only the truncated LIP isoform. C/EBPbeta-deficient mice and mice that express the LIP isoform only (L/L) display enhanced bone resorption. However, only C/EBPbeta-deficient mice suffer from osteopenia due to combined decrease in bone formation and enhanced resorption, whereas osteogenesis in LIP k.i. mutants exceeds enhanced bone resorption and results in increased bone mass. Although resolving the complexity of the described bone phenotypes requires further analysis, including constructing conditional and cell-type specific k.i. mutants, important conclusions can be drawn from our observations.
###end p 34
###begin title 35
###xml 5 9 5 6 <italic>&#946;</italic>
C/EBPbeta and bone homeostasis
###end title 35
###begin p 36
###xml 145 150 142 147 <italic>et al</italic>
###xml 136 156 133 153 <xref ref-type="bibr" rid="b64">Tominaga <italic>et al</italic>, 2008</xref>
###xml 193 198 190 195 <italic>et al</italic>
###xml 185 204 182 201 <xref ref-type="bibr" rid="b74">Zanotti <italic>et al</italic>, 2009</xref>
###xml 395 400 382 387 <italic>et al</italic>
###xml 385 406 372 393 <xref ref-type="bibr" rid="b66">Umayahara <italic>et al</italic>, 1999</xref>
###xml 418 423 405 410 <italic>et al</italic>
###xml 408 429 395 416 <xref ref-type="bibr" rid="b19">Gutierrez <italic>et al</italic>, 2002</xref>
###xml 439 444 426 431 <italic>et al</italic>
###xml 431 450 418 437 <xref ref-type="bibr" rid="b45">Pereira <italic>et al</italic>, 2006</xref>
###xml 452 456 439 443 <xref ref-type="bibr" rid="b46">2007</xref>
###xml 468 473 455 460 <italic>et al</italic>
###xml 458 479 445 466 <xref ref-type="bibr" rid="b55">Shirakawa <italic>et al</italic>, 2006</xref>
###xml 612 617 596 601 <italic>c/ebp</italic>
###xml 621 624 602 605 <sup>&#8722;/&#8722;</sup>
###xml 647 652 628 633 <italic>et al</italic>
###xml 638 658 619 639 <xref ref-type="bibr" rid="b64">Tominaga <italic>et al</italic>, 2008</xref>
###xml 867 872 842 847 <italic>et al</italic>
###xml 859 878 834 853 <xref ref-type="bibr" rid="b74">Zanotti <italic>et al</italic>, 2009</xref>
###xml 1096 1101 1071 1076 <italic>et al</italic>
###xml 1087 1107 1062 1082 <xref ref-type="bibr" rid="b64">Tominaga <italic>et al</italic>, 2008</xref>
###xml 1226 1231 1201 1206 <italic>c/ebp</italic>
###xml 1235 1238 1207 1210 <sup>&#8722;/&#8722;</sup>
###xml 1244 1251 1216 1223 <italic>in vivo</italic>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 179 183 <span type="species:ncbi:10090">mice</span>
###xml 537 541 <span type="species:ncbi:10090">mice</span>
###xml 1239 1243 <span type="species:ncbi:10090">mice</span>
C/EBPbeta deficiency resulted in reduced postnatal osteogenesis, as suggested by recent findings obtained in prenatal and newborn mice (Tominaga et al, 2008), as well as in adult mice (Zanotti et al, 2009). C/EBPbeta therefore displays non-redundant functions as other C/EBP family members are co-expressed in osteogenesis (C/EBPdelta and the more distantly related CHOP (C/EBPzeta)) (Umayahara et al, 1999; Gutierrez et al, 2002; Pereira et al, 2006, 2007; Shirakawa et al, 2006), but do not rescue the phenotype of C/EBPbeta-deficient mice. Tominaga and colleagues showed osteoblast differentiation defects in c/ebpbeta-/- osteoblasts (Tominaga et al, 2008), whereas in our cell culture experiments, the differentiation potential of C/EBPbeta-deficient osteoblasts was not affected, as also observed when C/EBPbeta was downregulated in primary osteoblasts (Zanotti et al, 2009). This discrepancy might be related to differences in the genetic background that apparently causes a more severe phenotype in C57Bl/6 as illustrated by the strongly reduced mendelian ratio (data not shown) (Tominaga et al, 2008), in comparison with our results obtained from a mixed genetic background. Thus, the observed reduced osteogenesis in c/ebpbeta-/- mice in vivo may involve micro-environmental effects that impinge on osteoblast function.
###end p 36
###begin p 37
###xml 582 587 570 575 <italic>et al</italic>
###xml 577 593 565 581 <xref ref-type="bibr" rid="b22">Hata <italic>et al</italic>, 2005</xref>
###xml 604 609 592 597 <italic>et al</italic>
###xml 595 615 583 603 <xref ref-type="bibr" rid="b64">Tominaga <italic>et al</italic>, 2008</xref>
###xml 773 778 758 763 <italic>et al</italic>
###xml 760 784 745 769 <xref ref-type="bibr" rid="b36">Kowenz-Leutz <italic>et al</italic>, 1994</xref>
###xml 795 800 780 785 <italic>et al</italic>
###xml 786 806 771 791 <xref ref-type="bibr" rid="b71">Williams <italic>et al</italic>, 1995</xref>
###xml 813 818 798 803 <italic>et al</italic>
###xml 808 824 793 809 <xref ref-type="bibr" rid="b38">Lamb <italic>et al</italic>, 2003</xref>
###xml 829 834 814 819 <italic>et al</italic>
###xml 826 840 811 825 <xref ref-type="bibr" rid="b40">Mo <italic>et al</italic>, 2005</xref>
###xml 953 958 935 940 <italic>et al</italic>
###xml 948 964 930 946 <xref ref-type="bibr" rid="b38">Lamb <italic>et al</italic>, 2003</xref>
###xml 54 60 <span type="species:ncbi:10090">murine</span>
Interestingly, expression of the LIP isoform from the murine C/EBPbeta locus prevents the osteopenic phenotype, enhances osteoblast differentiation and even leads to an osteosclerotic phenotype in the animal. Our results therefore suggest that C/EBPbeta, even without its transactivation domain, carries out essential functions in osteogenesis. It has been suggested that the bZIP domain of C/EBPbeta might serve as a scaffold for the assembly of a transcriptionally functional complex consisting of C/EBPbeta, Runx2 and ATF4, which may enhance activation of osteogenic genes (Hata et al, 2005; Tominaga et al, 2008). Although LIP is thought to act as a transdominant inhibitor, it has also been suggested that long C/EBPbeta isoforms could act as repressors (Kowenz-Leutz et al, 1994; Williams et al, 1995; Lamb et al, 2003; Mo et al, 2005) and that LIP might abrogate repression by removal of long C/EBPbeta isoforms (repression of a repressor) (Lamb et al, 2003). The fact that we see both, up- and downregulated genes in C/EBPbeta-deficient osteoblasts, supports the notion that C/EBPbeta may function as both, activator and repressor in the same cell type and in a gene context specific manner. However, how exactly removal of the transactivation function of C/EBPbeta contributes to the enhanced gene expression in osteoblasts will require additional experiments.
###end p 37
###begin p 38
###xml 118 123 118 123 <italic>et al</italic>
###xml 109 129 109 129 <xref ref-type="bibr" rid="b21">Harrison <italic>et al</italic>, 2005</xref>
###xml 144 147 144 147 <italic>L/L</italic>
###xml 415 420 415 420 <italic>et al</italic>
###xml 406 426 406 426 <xref ref-type="bibr" rid="b21">Harrison <italic>et al</italic>, 2005</xref>
###xml 549 554 549 554 <italic>et al</italic>
###xml 540 560 540 560 <xref ref-type="bibr" rid="b64">Tominaga <italic>et al</italic>, 2008</xref>
###xml 24 39 <span type="species:ncbi:10090">transgenic mice</span>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 584 599 <span type="species:ncbi:10090">transgenic mice</span>
Collagen promoter based transgenic mice, which overexpress LIP in the osteoblast lineage develop osteopenia (Harrison et al, 2005), whereas the L/L k.i. mice described here display increased bone mass. This discrepancy could be due to dissociation of the coupling process between LIP expression in osteoblasts and osteoclasts, or to gene dosage effects. The LIP-transgene might be temporally misexpressed (Harrison et al, 2005) and the observed osteopenia has recently been suggested to be secondary to decreased OC expression in the bone (Tominaga et al, 2008). Moreover, in the LIP transgenic mice, all isoforms of the endogenous C/EBPbeta messenger RNA are still present and could contribute to the observed phenotype. In our study, LIP replaces the endogenous C/EBPbeta gene, resulting in the sole expression of LIP when C/EBPbeta becomes expressed. Cell type and/or conditional knock-in animals will have to be constructed to solve any remaining discrepancies and to unravel the molecular mechanism of LIP function in osteogenesis. Nevertheless, all data show that C/EBPbeta is part of the transcription factor network regulating bone cell functions.
###end p 38
###begin title 39
###xml 5 9 5 6 <italic>&#946;</italic>
C/EBPbeta controls osteoclastogenesis through mTOR mediated isoform switching and MafB gene regulation
###end title 39
###begin p 40
###xml 681 686 669 674 <italic>et al</italic>
###xml 669 692 657 680 <xref ref-type="bibr" rid="b18">Glantschnig <italic>et al</italic>, 2003</xref>
###xml 703 708 691 696 <italic>et al</italic>
###xml 694 714 682 702 <xref ref-type="bibr" rid="b34">Kneissel <italic>et al</italic>, 2004</xref>
###xml 779 784 767 772 <italic>et al</italic>
###xml 770 790 758 778 <xref ref-type="bibr" rid="b34">Kneissel <italic>et al</italic>, 2004</xref>
###xml 854 859 842 847 <italic>et al</italic>
###xml 848 865 836 853 <xref ref-type="bibr" rid="b7">Boyce <italic>et al</italic>, 2006</xref>
###xml 764 768 <span type="species:ncbi:10116">rats</span>
A major result of this study is the identification of C/EBPbeta as regulator of osteoclastogenesis. Lack of C/EBPbeta, or lack of the transactivating isoforms, resulted in the formation of enlarged, hyperactive osteoclasts in animals and in tissue culture. Alternative translation initiation from a single mRNA may generate different C/EBPbeta isoforms. The C/EBPbeta isoform ratio is adjusted by an uORF that senses the activity status of the translation machinery, in particular the eukaryotic translation initiation factor eIF4E, which is controlled by the mTOR pathway. Rapamycin treatment has been shown to inhibit osteoclastogenesis in bone marrow cell cultures (Glantschnig et al, 2003; Kneissel et al, 2004) and to prevent ovariectomy-induced bone loss in rats (Kneissel et al, 2004), yet the mechanism downstream of mTOR remained unknown (Boyce et al, 2006). Our data provide the genetic link and a rational explanation for the rapamycin effect by showing that it depends on switching between C/EBPbeta isoforms.
###end p 40
###begin p 41
###xml 34 39 34 39 <italic>c/ebp</italic>
###xml 62 65 59 62 <italic>L/L</italic>
###xml 436 441 427 432 <italic>c/ebp</italic>
###xml 445 448 433 436 <sup>&#8722;/&#8722;</sup>
###xml 456 459 444 447 <italic>L/L</italic>
The phenotypic coincidence of the c/ebpbeta knock-out and the L/L genotypes on one hand and the surprisingly large overlap between genes that are activated by LAP and by rapamycin on the other hand suggested that full-length C/EBPbeta may induce expression of an osteolytic inhibitor. Loss of an inhibitor of osteoclastogenesis as the mechanism of C/EBPbeta activation is consistent with the gain-of-function phenotype observed in both c/ebpbeta-/- and in L/L cells.
###end p 41
###begin p 42
###xml 97 102 97 102 <italic>c/ebp</italic>
###xml 201 206 198 203 <italic>et al</italic>
###xml 196 212 193 209 <xref ref-type="bibr" rid="b52">Sadl <italic>et al</italic>, 2002</xref>
###xml 224 229 221 226 <italic>et al</italic>
###xml 214 235 211 232 <xref ref-type="bibr" rid="b41">Moriguchi <italic>et al</italic>, 2006</xref>
###xml 287 309 284 306 <xref ref-type="bibr" rid="b12">Cordes and Barsh, 1994</xref>
###xml 348 353 345 350 <italic>et al</italic>
###xml 340 359 337 356 <xref ref-type="bibr" rid="b6">Blanchi <italic>et al</italic>, 2003</xref>
###xml 490 495 487 492 <italic>et al</italic>
###xml 482 501 479 498 <xref ref-type="bibr" rid="b56">Sieweke <italic>et al</italic>, 1996</xref>
###xml 509 514 506 511 <italic>et al</italic>
###xml 503 520 500 517 <xref ref-type="bibr" rid="b31">Kelly <italic>et al</italic>, 2000</xref>
###xml 601 606 598 603 <italic>et al</italic>
###xml 596 612 593 609 <xref ref-type="bibr" rid="b4">Aziz <italic>et al</italic>, 2006</xref>
###xml 654 659 651 656 <italic>et al</italic>
###xml 644 665 641 662 <xref ref-type="bibr" rid="b41">Moriguchi <italic>et al</italic>, 2006</xref>
###xml 873 878 870 875 <italic>et al</italic>
###xml 869 884 866 881 <xref ref-type="bibr" rid="b32">Kim <italic>et al</italic>, 2007</xref>
We found that MafB was strongly upregulated by LAP and by rapamycin and suppressed by LIP and by c/ebpbeta deficiency. MafB is a bZIP transcription factor, important for podocyte differentiation (Sadl et al, 2002; Moriguchi et al, 2006), rhombomere specification in the early hindbrain (Cordes and Barsh, 1994) and for respiratory control (Blanchi et al, 2003). Moreover, in the haematopoietic system, MafB regulates myeloid differentiation and promotes macrophage differentiation (Sieweke et al, 1996; Kelly et al, 2000). MafB deficiency in macrophages results in an altered actin organization (Aziz et al, 2006) and reduced F4/80 expression (Moriguchi et al, 2006). Recently, MafB has been associated with osteoclast differentiation. MafB negatively regulates RANK-L-induced osteoclastogenesis by attenuating DNA binding of the key regulators NFATc1, c-Fos and Mitf (Kim et al, 2007).
###end p 42
###begin p 43
###xml 145 150 145 150 <italic>c/ebp</italic>
###xml 154 157 151 154 <sup>&#8722;/&#8722;</sup>
###xml 162 165 159 162 <italic>L/L</italic>
###xml 318 323 315 320 <italic>et al</italic>
###xml 314 329 311 326 <xref ref-type="bibr" rid="b32">Kim <italic>et al</italic>, 2007</xref>
###xml 409 414 406 411 <italic>et al</italic>
###xml 398 420 395 417 <xref ref-type="bibr" rid="b60">Takayanagi <italic>et al</italic>, 2002</xref>
###xml 430 435 427 432 <italic>et al</italic>
###xml 422 441 419 438 <xref ref-type="bibr" rid="b3">Asagiri <italic>et al</italic>, 2005</xref>
###xml 454 459 451 456 <italic>et al</italic>
###xml 443 465 440 462 <xref ref-type="bibr" rid="b2">Aliprantis <italic>et al</italic>, 2008</xref>
###xml 533 538 530 535 <italic>et al</italic>
###xml 529 544 526 541 <xref ref-type="bibr" rid="b33">Kim <italic>et al</italic>, 2008</xref>
###xml 576 581 569 574 <italic>et al</italic>
###xml 571 587 564 580 <xref ref-type="bibr" rid="b44">Peng <italic>et al</italic>, 2001</xref>
###xml 598 603 591 596 <italic>et al</italic>
###xml 589 609 582 602 <xref ref-type="bibr" rid="b29">Kaminuma <italic>et al</italic>, 2008</xref>
###xml 629 634 622 627 <italic>c/ebp</italic>
###xml 638 641 628 631 <sup>&#8722;/&#8722;</sup>
###xml 646 649 636 639 <italic>L/L</italic>
###xml 854 876 836 858 <xref ref-type="bibr" rid="b50">Rodan and Martin, 2000</xref>
###xml 878 892 860 874 <xref ref-type="bibr" rid="b23">Helfrich, 2003</xref>
###xml 894 919 876 901 <xref ref-type="bibr" rid="b63">Teitelbaum and Ross, 2003</xref>
###xml 921 946 903 928 <xref ref-type="bibr" rid="b16">Ehrlich and Roodman, 2005</xref>
###xml 1007 1012 985 990 <italic>c/ebp</italic>
###xml 1016 1019 991 994 <sup>&#8722;/&#8722;</sup>
###xml 1023 1026 998 1001 <italic>L/L</italic>
###xml 1121 1126 1096 1101 <italic>et al</italic>
###xml 1117 1132 1092 1107 <xref ref-type="bibr" rid="b37">Lam <italic>et al</italic>, 2000</xref>
###xml 1141 1146 1116 1121 <italic>et al</italic>
###xml 1134 1152 1109 1127 <xref ref-type="bibr" rid="b17">Fuller <italic>et al</italic>, 2002</xref>
###xml 1158 1163 1133 1138 <italic>et al</italic>
###xml 1154 1169 1129 1144 <xref ref-type="bibr" rid="b33">Kim <italic>et al</italic>, 2008</xref>
###xml 1027 1031 <span type="species:ncbi:10090">mice</span>
Here, we show that inhibition of osteoclastogenesis by either expression of LAP or by rapamycin depends on MafB. Furthermore, and as observed in c/ebpbeta-/- and L/L osteoclasts, decreased levels of MafB result in increased levels of the key regulator of osteoclastogenesis NFATc1 and its downstream target OSCAR (Kim et al, 2007). NFATc1 is not only a key regulator of osteoclast differentiation (Takayanagi et al, 2002; Asagiri et al, 2005; Aliprantis et al, 2008), but also regulates the cell fusion genes ATP6v0d2, DC-STAMP (Kim et al, 2008) and TNFalpha expression (Peng et al, 2001; Kaminuma et al, 2008). We found that in c/ebpbeta-/- and L/L osteoclasts the cell fusion genes ATP6v0d2, DC-STAMP and TNFalpha, were upregulated. Hyperactive osteoclasts and increased TNFalpha production are often involved in bone diseases, including osteoporosis (Rodan and Martin, 2000; Helfrich, 2003; Teitelbaum and Ross, 2003; Ehrlich and Roodman, 2005). Autocrine TNFalpha production in osteoclasts derived from c/ebpbeta-/- or L/L mice indeed contributed to augmented osteoclastogenesis, consistent with earlier reports (Lam et al, 2000; Fuller et al, 2002; Kim et al, 2008).
###end p 43
###begin p 44
###xml 220 228 214 222 <xref ref-type="fig" rid="f9">Figure 9</xref>
###xml 305 310 <span type="species:ncbi:9606">human</span>
Therefore, our data provide strong genetic and mechanistical evidence that adjustment of the C/EBPbeta isoform ratio by alternative translation of C/EBPbeta determines the MafB expresssion status and osteoclastogenesis (Figure 9). We speculate that changes in C/EBPbeta isoform ratio could be involved in human bone diseases and drugs targeting translational control and thus altering the C/EBPbeta isoform ratio may possibly enable novel therapeutic strategies in the management and treatment of osteolytic bone diseases, such as osteoporosis and multiple myeloma.
###end p 44
###begin title 45
Materials and methods
###end title 45
###begin title 46
###xml 19 23 19 20 <italic>&#946;</italic>
###xml 31 35 <span type="species:ncbi:10090">mice</span>
Generation of c/ebpbeta mutant mice
###end title 46
###begin p 47
###xml 4 9 4 9 <italic>c/ebp</italic>
###xml 74 79 71 76 <italic>et al</italic>
###xml 65 85 62 82 <xref ref-type="bibr" rid="b59">Sterneck <italic>et al</italic>, 1997</xref>
###xml 153 171 150 168 <xref ref-type="supplementary-material" rid="S1">Supplementary data</xref>
###xml 204 209 201 206 <italic>c/ebp</italic>
###xml 428 433 422 427 <italic>c/ebp</italic>
###xml 452 455 443 446 <italic>LIP</italic>
###xml 24 29 <span type="species:ncbi:10090">mouse</span>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 241 245 <span type="species:ncbi:10090">mice</span>
###xml 265 269 <span type="species:ncbi:10090">Mice</span>
###xml 312 316 <span type="species:ncbi:10090">Mice</span>
###xml 465 469 <span type="species:ncbi:10090">mice</span>
###xml 691 695 <span type="species:ncbi:10090">mice</span>
###xml 754 758 <span type="species:ncbi:10090">Mice</span>
###xml 787 792 <span type="species:ncbi:10090">mouse</span>
The c/ebpbeta knock-out mouse strain has been described earlier (Sterneck et al, 1997) and the LIP knock-in mice have been generated as described in the Supplementary data. The genetic background of both c/ebpbeta knock-out and LIP knock-in mice was 129 x C57Bl/6. Mice were kept under pathogen-free conditions. Mice were bred from heterozygous breeders and littermates were compared with each other. The WT littermates of both c/ebpbeta knock-out and LIP knock-in mice displayed similar bone parameters (bone histomorphometry and in cell culture experiments). Therefore, the WT control group is displayed as a single group. Animals were analysed at the age of 8 weeks. Both female and male mice showed the same phenotype and were analysed as one group. Mice were provided with standard mouse diet and water ad libitum on a 12-h light-dark cycle. All procedures and animal experiments were conducted in compliance with protocols approved by the institutional Animal Care and Use Committee.
###end p 47
###begin title 48
Osteoclast cultures
###end title 48
###begin p 49
###xml 92 97 92 97 <italic>et al</italic>
###xml 83 103 83 103 <xref ref-type="bibr" rid="b13">de Vries <italic>et al</italic>, 2005</xref>
###xml 606 611 600 605 <italic>et al</italic>
###xml 595 617 589 611 <xref ref-type="bibr" rid="b60">Takayanagi <italic>et al</italic>, 2002</xref>
###xml 858 863 852 857 <italic>et al</italic>
###xml 849 869 843 863 <xref ref-type="bibr" rid="b13">de Vries <italic>et al</italic>, 2005</xref>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 207 213 <span type="species:ncbi:10090">murine</span>
###xml 278 284 <span type="species:ncbi:9913">bovine</span>
###xml 948 954 <span type="species:ncbi:10090">murine</span>
Primary bone marrow cells from 8-week-old mice were cultured as described earlier (de Vries et al, 2005), in the presence of 30 ng/ml recombinant M-CSF (R&D Systems) and with or without 20 ng/ml recombinant murine RANK-L-TEC (R&D Systems) for 6 days on plastic or for 7 days on bovine cortical bone slices. The TNFalpha antagonist Etanercept (Enbrel) was used at 10 mug/ml. Rapamycin (0.5 muM) and Etanercept treatment were started at day 0. TRACP staining was performed with the leukocyte acid phosphatase kit (Sigma). For osteoclast cultures of 2 days, BMMs were prepared as described before (Takayanagi et al, 2002) and osteoclast differentiation was induced as described above for 2 days. To assess the resorptive activity of osteoclasts, bone slices were stained with coomassie brilliant blue to visualize resorption pits as described earlier (de Vries et al, 2005). RAW264.7 cells (ATCC) were cultured in the presence of 20 ng/ml recombinant murine RANK-L-TEC for 6 days to induce osteoclast differentiation.
###end p 49
###begin title 50
Osteoblast cultures
###end title 50
###begin p 51
###xml 107 112 107 112 <italic>et al</italic>
###xml 100 118 100 118 <xref ref-type="bibr" rid="b26">Jochum <italic>et al</italic>, 2000</xref>
###xml 356 371 356 371 <xref ref-type="bibr" rid="b67">van't Hof, 2003</xref>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
Primary osteoblast precursors were cultured from neonatal mice (1-6 days old) as described earlier (Jochum et al, 2000). After 14 and 21 days of culture, cells were fixed stained for ALP and mineralized bone nodules were identified by staining with 2% Alizarin Red S (Sigma). Co-cultures of osteoblasts and osteoclasts were performed as described earlier (van't Hof, 2003).
###end p 51
###begin title 52
Protein analysis
###end title 52
###begin p 53
All cell types were lyzed with RIPA buffer. For osteoblasts, proteins were isolated before adding osteoblastogenic agents (considered as preosteoblasts), 7 days after adding osteogenic agents (considered as osteoblasts) and at the appearance of bone nodules (considered as mature osteoblasts). For osteoclasts, proteins were isolated from bone marrow derived monocytic precursors at day 0, 3 and 6 after addition of M-CSF and RANK-L. For the liver protein extracts, 8-week-old animals were used. Proteins were separated on 15% SDS-polyacrylamide gels, transferred onto nitrocellulose membranes and probed with anti-C/EBPbeta (C-19), anti-alpha-tubulin or anti-alpha-actin (all from Santa Cruz Biotechnology Inc.), anti-MafB (Abcam) and anti-cleaved caspase-3 (Cell Signaling) using standard procedures.
###end p 53
###begin title 54
Biochemical assays
###end title 54
###begin p 55
###xml 0 7 0 7 <italic>In vivo</italic>
In vivo osteoclast activity was determined by measuring total DPD cross-links in urine samples, which was expressed relative to urinary creatinine levels (Metra Biosystems, Inc.). Eight animals of each genotype were analysed.
###end p 55
###begin p 56
Media samples of osteoclast cultures were collected on day 6 of cell culture and used for quantifying TNFalpha protein levels by ELISA (BD Biosciences).
###end p 56
###begin title 57
RNA isolation and real-time RT-PCR
###end title 57
###begin p 58
###xml 382 387 382 387 <italic>et al</italic>
###xml 373 393 373 393 <xref ref-type="bibr" rid="b14">de Vries <italic>et al</italic>, 2006</xref>
Total RNA of primary osteoclasts was isolated on day 6 of culture using the RNeasy mini kit (Qiagen) and cDNA was synthesized using the SuperScript II reverse transcriptase, as described by the manufacturer (Invitrogen). Real-time RT-PCR was performed on an ABI PRISM 7000 (Applied Biosystems) using the SYBR Green PCR Master Mix (Applied Biosystems) as described earlier (de Vries et al, 2006). RNA of osteoblasts was isolated using TriPure isolation reagent (Roche) and cDNA was synthesized as described for the osteoclasts. Real-time RT-PCR analysis was performed on a LightCycler type II (Roche) using the SYBR Green PCR Master Mix (Roche). Expression of GAPDH was used to normalize individual RNA expression levels. The data are expressed as relative RNA expression levels and calculated using the comparative CT method. The WT expression level was set at 1. Sequences of primer pairs used can be obtained upon request.
###end p 58
###begin title 59
###xml 19 23 19 20 <italic>&#946;</italic>
Expression of C/EBPbeta isoforms in RAW264.7 cells
###end title 59
###begin p 60
###xml 17 22 17 22 <italic>c/ebp</italic>
###xml 36 39 33 36 <italic>LAP</italic>
###xml 44 47 41 44 <italic>LIP</italic>
###xml 13 16 <span type="species:ncbi:10116">rat</span>
The cDNAs of rat c/ebpbeta isoforms LAP and LIP were cloned into a pIRES-EGFP vector. RAW264.7 cells were transfected with FuGENE (Roche) and after 48 h, the cells were washed once and selected for 2-3 weeks in the presence of neomycin. EGFP-positive cells were sorted by FACS and were induced to differentiate into osteoclasts as described above. Three independent experiments were performed.
###end p 60
###begin title 61
Gene array analyses and shRNA experiments
###end title 61
###begin p 62
###xml 359 364 <span type="species:ncbi:10090">mouse</span>
For gene array analyses, total RNA was isolated from RAW264.7 control cells (empty vector) treated with rapamycin or cells expressing LAP, using the RNeasy mini kit (Qiagen). The cells were induced to differentiate into osteoclasts by treatment with 20 ng/ml RANK-L for 48 h. RNA (1 mug) expression analysis was performed using the Agilent 4x44K whole genome mouse array (Agilent) and analysed per manufacturer's instructions at ImaGenes (Berlin, Germany). Each gene array experiment was performed in triplicate.
###end p 62
###begin p 63
###xml 113 118 <span type="species:ncbi:10090">mouse</span>
###xml 301 306 <span type="species:ncbi:10090">mouse</span>
For short hairpin interfering RNA experiments, shRNAs were expressed in psiRNA (Invivogen). shRNA oligos against mouse MafB were designed using the 'InvivoGen's siRNA Wizard' program (). As control, a non-specific shRNA was used. Sequences targeted by shRNAs: Control (5'-GTCCATCGAACTCAGTAGCT-3') and mouse MafB (5'-GGCAACTAACGCTGCAACTCT-3'). Cells were transfected with FuGENE (Roche) and after 48 h, the cells were washed once and selected for 2-3 weeks in the presence of zeocin. EGFP-positive cells were sorted by FACS and were induced to differentiate into osteoclasts as described above.
###end p 63
###begin title 64
Luciferase gene reporter assay
###end title 64
###begin p 65
###xml 216 221 216 221 <italic>et al</italic>
###xml 210 227 210 227 <xref ref-type="bibr" rid="b25">Huang <italic>et al</italic>, 2000</xref>
###xml 284 287 281 284 <sup>&#8722;/&#8722;</sup>
###xml 315 320 312 317 <italic>Trans</italic>
###xml 419 422 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
The MafB luciferase reporter plasmid containing the -609 bp MafB promoter inserted in the promoter-less luciferase vector pGVB2 was a gift from M Sakai (Hokkaido University School of Medicine, Sapporo, Japan) (Huang et al, 2000). RAW264.7 cells or spontaneously immortalized C/EBPbeta-/- MEFs were transfected with TransIT-LT1 (Mirus) with the MafB reporter plasmid, the indicated C/EBPbeta expression constructs and a CMV-promoter driven Renilla luciferase vector as an internal control at a ratio of 5:1. RANK-L or rapamycin were added to the RAW264.7 cells and rapamycin to the MEFs 7 h after transfection. Firefly and Renilla luciferase activity was assayed 48 h after transfection. Firefly luciferase activity was normalized to Renilla luciferase to control for transfection efficiency. The data are representative of three independent experiments, duplicates are plotted as the mean+/-s.e.m.
###end p 65
###begin title 66
Statistical analysis
###end title 66
###begin p 67
###xml 61 66 59 64 <italic>c/ebp</italic>
###xml 70 73 65 68 <sup>&#8722;/&#8722;</sup>
###xml 78 81 73 76 <italic>LIP</italic>
###xml 218 219 213 214 <italic>P</italic>
###xml 87 91 <span type="species:ncbi:10090">mice</span>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
In all experiments, data are expressed as means+/-s.e.m. and c/ebpbeta-/- and LIP k.i. mice were compared with WT mice. Statistical differences between groups were determined by one-way ANOVA with Dunnett post-test. A P-value of <0.05 was considered to be statistically significant.
###end p 67
###begin title 68
Supplementary Material
###end title 68
###begin p 69
Supplementary Figure S1
###end p 69
###begin p 70
Supplementary Figure S2
###end p 70
###begin p 71
Supplementary Figures Legends
###end p 71
###begin p 72
Supplementary Table 1
###end p 72
###begin p 73
Supplementary Data
###end p 73
###begin p 74
###xml 126 131 <span type="species:ncbi:10090">mouse</span>
We are indebted to Drs C Birchmeier and T Muller (MDC, Berlin, Germany) for providing reagents, advice and help with targeted mouse genetics. We are grateful to Dr J-P David (German Rheumatism Research Center Berlin, Germany) and Dr GR Burmester (Charite, University Medicine Berlin, Germany) for providing Etanercept, Dr M Sakai (Department of Biochemistry, Hokkaido University School of Medicine, Sapporo Japan) for providing the MafB luciferase reporter construct. Furthermore, we thank Dr H-P Rahn (MDC, Berlin, Germany) for FACS sorting, R Zarmstorff and P Gossen-Heinrich for technical assistance. We also thank Dr BCJ van der Eerden (Erasmus Medical Center, Rotterdam, The Netherlands) for helpful discussions and advice as well as Dr K Zaragoza, Dr K Wethmar and the other members of the Leutz lab for discussions. This work was supported by an individual Marie Curie fellowship from the European Community to JJS (MEIF-CT-2005-009611) and the Berliner Krebsgesellschaft (LEFF200708).
###end p 74
###begin p 75
The authors declare that they have no conflict of interest.
###end p 75
###begin article-title 76
IL-6 and NF-IL6 in acute-phase response and viral infection. 
###end article-title 76
###begin article-title 77
###xml 10 14 <span type="species:ncbi:10090">mice</span>
NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. 
###end article-title 77
###begin article-title 78
Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. 
###end article-title 78
###begin article-title 79
Development of macrophages with altered actin organization in the absence of MafB. 
###end article-title 79
###begin article-title 80
Essential requirement of CCAAT/enhancer binding proteins in embryogenesis. 
###end article-title 80
###begin article-title 81
MafB deficiency causes defective respiratory rhythmogenesis and fatal central apnea at birth. 
###end article-title 81
###begin article-title 82
Future anti-catabolic therapeutic targets in bone disease. 
###end article-title 82
###begin article-title 83
Osteoclast differentiation and activation. 
###end article-title 83
###begin article-title 84
Translational control of C/EBPalpha and C/EBPbeta isoform expression. 
###end article-title 84
###begin article-title 85
Translational control of gene expression and disease. 
###end article-title 85
###begin article-title 86
Efficacy of etanercept for wear debris-induced osteolysis. 
###end article-title 86
###begin article-title 87
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
The mouse segmentation gene kr encodes a novel basic domain-leucine zipper transcription factor. 
###end article-title 87
###begin article-title 88
###xml 29 37 29 37 <italic>in vitro</italic>
###xml 42 49 42 49 <italic>in vivo</italic>
Effect of CD44 deficiency on in vitro and in vivo osteoclast formation. 
###end article-title 88
###begin article-title 89
Gingival fibroblasts are better at inhibiting osteoclast formation than periodontal ligament fibroblasts. 
###end article-title 89
###begin article-title 90
A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. 
###end article-title 90
###begin article-title 91
The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma. 
###end article-title 91
###begin article-title 92
TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. 
###end article-title 92
###begin article-title 93
M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. 
###end article-title 93
###begin article-title 94
CCAAT/enhancer-binding proteins (C/EBP) beta and delta activate osteocalcin gene transcription and synergize with Runx2 at the C/EBP element to regulate bone-specific expression. 
###end article-title 94
###begin article-title 95
Control of osteoblast function and regulation of bone mass. 
###end article-title 95
###begin article-title 96
###xml 144 159 <span type="species:ncbi:10090">transgenic mice</span>
Col1a1 promoter-targeted expression of p20 CCAAT enhancer-binding protein beta (C/EBPbeta), a truncated C/EBPbeta isoform, causes osteopenia in transgenic mice. 
###end article-title 96
###begin article-title 97
A CCAAT/enhancer binding protein beta isoform, liver-enriched inhibitory protein, regulates commitment of osteoblasts and adipocytes. 
###end article-title 97
###begin article-title 98
Osteoclast diseases. 
###end article-title 98
###begin article-title 99
C/EBPbeta is required for 'emergency' granulopoiesis. 
###end article-title 99
###begin article-title 100
###xml 57 62 <span type="species:ncbi:10090">mouse</span>
Molecular cloning and functional characterization of the mouse MafB gene. 
###end article-title 100
###begin article-title 101
###xml 47 51 <span type="species:ncbi:10090">mice</span>
Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. 
###end article-title 101
###begin article-title 102
Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors. 
###end article-title 102
###begin article-title 103
A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-kappaB activity in Hodgkin and anaplastic large cell lymphomas. 
###end article-title 103
###begin article-title 104
Differential contribution of NFATc2 and NFATc1 to TNF-alpha gene expression in T cells. 
###end article-title 104
###begin article-title 105
Reaching a genetic and molecular understanding of skeletal development. 
###end article-title 105
###begin article-title 106
MafB is an inducer of monocytic differentiation. 
###end article-title 106
###begin article-title 107
MafB negatively regulates RANKL-mediated osteoclast differentiation. 
###end article-title 107
###begin article-title 108
NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). 
###end article-title 108
###begin article-title 109
Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. 
###end article-title 109
###begin article-title 110
A C/EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes. 
###end article-title 110
###begin article-title 111
Novel mechanism of C/EBP beta (NF-M) transcriptional control: activation through derepression. 
###end article-title 111
###begin article-title 112
TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. 
###end article-title 112
###begin article-title 113
###xml 78 83 <span type="species:ncbi:9606">human</span>
A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. 
###end article-title 113
###begin article-title 114
Osteoclast-derived activity in the coupling of bone formation to resorption. 
###end article-title 114
###begin article-title 115
Histone H3 tail positioning and acetylation by the c-Myb but not the v-Myb DNA-binding SANT domain. 
###end article-title 115
###begin article-title 116
MafB is essential for renal development and F4/80 expression in macrophages. 
###end article-title 116
###begin article-title 117
The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. 
###end article-title 117
###begin article-title 118
###xml 80 87 80 87 <italic>in vivo</italic>
Distinct C/EBPalpha motifs regulate lipogenic and gluconeogenic gene expression in vivo. 
###end article-title 118
###begin article-title 119
NFATc1 and NFATc2 together control both T and B cell activation and differentiation. 
###end article-title 119
###begin article-title 120
C/EBP homologous protein is necessary for normal osteoblastic function. 
###end article-title 120
###begin article-title 121
CCAAT/Enhancer-binding protein homologous protein (CHOP) decreases bone formation and causes osteopenia. 
###end article-title 121
###begin article-title 122
Interaction between osteoblast and osteoclast: impact in bone disease. 
###end article-title 122
###begin article-title 123
The role of C/EBP isoforms in the control of inflammatory and native immunity functions. 
###end article-title 123
###begin article-title 124
CCAAT/enhancer-binding proteins: structure, function and regulation. 
###end article-title 124
###begin article-title 125
Therapeutic approaches to bone diseases. 
###end article-title 125
###begin article-title 126
Adipocyte differentiation from the inside out. 
###end article-title 126
###begin article-title 127
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
The mouse Kreisler (Krml1/MafB) segmentation gene is required for differentiation of glomerular visceral epithelial cells. 
###end article-title 127
###begin article-title 128
###xml 86 90 <span type="species:ncbi:10090">mice</span>
Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. 
###end article-title 128
###begin article-title 129
Stop and go: anti-proliferative and mitogenic functions of the transcription factor C/EBPbeta. 
###end article-title 129
###begin article-title 130
CCAAT/enhancer-binding protein homologous protein (CHOP) regulates osteoblast differentiation. 
###end article-title 130
###begin article-title 131
MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation. 
###end article-title 131
###begin article-title 132
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. 
###end article-title 132
###begin article-title 133
CCAAT/enhancer binding protein beta is a neuronal transcriptional regulator activated by nerve growth factor receptor signaling. 
###end article-title 133
###begin article-title 134
An essential role for C/EBPbeta in female reproduction. 
###end article-title 134
###begin article-title 135
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. 
###end article-title 135
###begin article-title 136
Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. 
###end article-title 136
###begin article-title 137
###xml 39 43 <span type="species:ncbi:10090">mice</span>
Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. 
###end article-title 137
###begin article-title 138
Genetic regulation of osteoclast development and function. 
###end article-title 138
###begin article-title 139
CCAAT/enhancer-binding protein beta promotes osteoblast differentiation by enhancing Runx2 activity with ATF4. 
###end article-title 139
###begin article-title 140
The C/EBPbeta isoform 34-kDa LAP is responsible for NF-IL-6-mediated gene induction in activated macrophages, but is not essential for intracellular bacteria killing. 
###end article-title 140
###begin article-title 141
CCAAT/enhancer-binding protein delta is a critical regulator of insulin-like growth factor-I gene transcription in osteoblasts. 
###end article-title 141
###begin article-title 142
###xml 28 33 <span type="species:ncbi:10090">mouse</span>
Osteoclast formation in the mouse coculture assay. 
###end article-title 142
###begin article-title 143
The epithelial Ca2+ channel TRPV5 is essential for proper osteoclastic bone resorption. 
###end article-title 143
###begin article-title 144
Chromatin remodeling and transcriptional activity of the bone-specific osteocalcin gene require CCAAT/enhancer-binding protein beta-dependent recruitment of SWI/SNF activity. 
###end article-title 144
###begin article-title 145
###xml 44 48 <span type="species:ncbi:10090">mice</span>
HDAC1 promotes liver proliferation in young mice via interactions with C/EBPbeta. 
###end article-title 145
###begin article-title 146
CRP2 (C/EBP beta) contains a bipartite regulatory domain that controls transcriptional activation, DNA binding and cell specificity. 
###end article-title 146
###begin article-title 147
Regulation of CCAAT/enhancer-binding protein-beta isoform synthesis by alternative translational initiation at multiple AUG start sites. 
###end article-title 147
###begin article-title 148
DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. 
###end article-title 148
###begin article-title 149
Misexpression of CCAAT/enhancer binding protein beta (C/EBPbeta) causes osteopenia. 
###end article-title 149
###begin article-title 150
Induction of granulocytic differentiation by 2 pathways. 
###end article-title 150
###begin p 151
###xml 40 41 37 38 <bold>A</bold>
###xml 314 315 304 305 <bold>B</bold>
###xml 317 318 307 308 <bold>C</bold>
###xml 629 630 614 615 <bold>D</bold>
###xml 690 691 672 673 <sup>*</sup>
###xml 807 808 789 790 <bold>E</bold>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
Expression of C/EBPbeta in bone cells. (A) Immunohistochemistry of the proximal tibia of 4-week-old mice showing expression of C/EBPbeta protein (brown precipitate) in the different bone cell types. Lightgreen was used as counterstain. Scale bar, 200 mum. C/EBPbeta protein expression in osteoblasts (arrowheads) (B, C), whereas no C/EBPbeta protein was detected in differentiated osteoclasts (OC) (arrow), which were identified as large multinucleated cells attached to the bone surface (scale bar, 50 mum) or (C) in osteocytes (arrow, scale bar, 50 mum). Tb, trabeculae; GP, growth plate; BM, bone marrow; Cort, cortical bone (D) Western blot analysis of C/EBPbeta isoform expression (LAP*, LAP and LIP) during osteoblast differentiation (pOB, preosteoblasts; OB, osteoblast; mOB, mature osteoblast) and (E) during osteoclast differentiation of bone marrow derived monocytic precursors on the indicated days (d0, d3, d6) after M-CSF and RANK-L addition. Loading was controlled by analysis of alpha-tubulin and alpha-actin expression, respectively. UD, undefined bands, which cross-react with the C/EBPbeta antibody.
###end p 151
###begin p 152
###xml 35 38 35 38 <italic>LIP</italic>
###xml 55 56 55 56 <bold>A</bold>
###xml 194 199 191 196 <italic>c/ebp</italic>
###xml 297 302 291 296 <italic>c/ebp</italic>
###xml 365 370 356 361 <italic>c/ebp</italic>
###xml 640 641 628 629 <sup>*</sup>
###xml 770 771 758 759 <bold>B</bold>
###xml 1179 1180 1167 1168 <bold>C</bold>
###xml 1335 1340 1316 1321 <italic>c/ebp</italic>
###xml 1344 1347 1322 1325 <sup>&#8722;/&#8722;</sup>
###xml 1354 1355 1332 1333 <italic>L</italic>
###xml 1356 1357 1334 1335 <italic>L</italic>
###xml 1359 1362 1337 1340 <italic>LIP</italic>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 1246 1250 <span type="species:ncbi:10090">mice</span>
###xml 1324 1328 <span type="species:ncbi:10090">mice</span>
###xml 1348 1352 <span type="species:ncbi:10090">mice</span>
###xml 1368 1372 <span type="species:ncbi:10090">mice</span>
###xml 1397 1401 <span type="species:ncbi:10090">mice</span>
Generation and characterization of LIP knock-in mice. (A) Schematic representation of the targeting strategy used to generate a knock-in (k.i.) of the LIP isoform of C/EBPbeta in the endogenous c/ebpbeta locus by homologous recombination in embryonic stem (ES) cells. The structure of the genomic c/ebpbeta locus, targeting vector and mutated allele are shown. The c/ebpbeta gene is intronless and depicted as filled red box and LIP as dashed red box. The arrow indicates the direction of gene transcription. The DNA fragments and their sizes revealed by Southern blot analysis are indicated by thick coloured lines. B, BamHI; N, NotI; R, R*, EcoRI; S, SalI; X, XhoI; Xa, XbaI. Neo, neomycin resistance gene; LoxP sites (black triangles); P5': 5' probe; P3': 3' probe. (B) Southern blot analysis of ES cell DNA. Genomic DNA of targeted ES cells was isolated from two clones and digested with EcoRI and then hybridized with the 5' probe (in purple). The WT and mutant allele are detected as 4.5 and 3.0 kb fragments, respectively. BamHI digested DNA was hybridized with the 3' probe (in blue) that detected a 7.0-kb fragment in the WT and a 7.8-kb fragment in the mutant allele. (C) C/EBPbeta protein expression in livers isolated from 8-week-old mice. Loading was controlled by analysis of alpha-tubulin expression. +/+, WT mice; -/-, c/ebpbeta-/- mice; L/L, LIP k.i. mice; +/L, heterozygous k.i. mice.
###end p 152
###begin p 153
###xml 22 27 22 27 <italic>c/ebp</italic>
###xml 46 47 43 44 <bold>A</bold>
###xml 166 171 163 168 <italic>c/ebp</italic>
###xml 232 235 226 229 <italic>LIP</italic>
###xml 247 250 241 244 <italic>L/L</italic>
###xml 464 465 457 458 <bold>B</bold>
###xml 519 524 512 517 <italic>c/ebp</italic>
###xml 635 636 625 626 <bold>C</bold>
###xml 669 674 659 664 <italic>c/ebp</italic>
###xml 768 773 755 760 <italic>c/ebp</italic>
###xml 956 963 939 946 <italic>in vivo</italic>
###xml 1006 1007 989 990 <italic>n</italic>
###xml 1040 1045 1023 1028 <italic>c/ebp</italic>
###xml 1049 1052 1029 1032 <sup>&#8722;/&#8722;</sup>
###xml 1059 1060 1039 1040 <italic>L</italic>
###xml 1061 1062 1041 1042 <italic>L</italic>
###xml 1064 1067 1044 1047 <italic>LIP</italic>
###xml 1115 1116 1093 1094 <sup>*</sup>
###xml 1116 1117 1094 1095 <italic>P</italic>
###xml 1124 1126 1102 1104 <sup>**</sup>
###xml 1126 1127 1104 1105 <italic>P</italic>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
###xml 125 129 <span type="species:ncbi:10090">mice</span>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
###xml 241 245 <span type="species:ncbi:10090">mice</span>
###xml 276 280 <span type="species:ncbi:10090">mice</span>
###xml 536 540 <span type="species:ncbi:10090">mice</span>
###xml 686 690 <span type="species:ncbi:10090">mice</span>
###xml 785 789 <span type="species:ncbi:10090">mice</span>
###xml 1029 1033 <span type="species:ncbi:10090">mice</span>
###xml 1053 1057 <span type="species:ncbi:10090">mice</span>
###xml 1073 1077 <span type="species:ncbi:10090">mice</span>
Affected bone mass in c/ebpbeta mutant mice. (A) Histological analyses (haematoxylin-eosin staining) of tibiae of 8-week-old mice, showing an osteopenic phenotype in c/ebpbeta-deficient mice (-/-) and an osteosclerotic phenotype in LIP k.i. mice (L/L), compared with WT (+/+) mice. Scale bar, 100 mum. Bar graph displays the histomorphometric quantification of the bone volume (BV/TV, bone volume/total volume). GP, growth plate; Tb, trabeculae; BM, bone marrow. (B) Images of double calcein labelled bones from WT and c/ebpbeta mutant mice showing the mineral apposition rate (MAR) and the bone formation rate/bone surface (BFR/BS). (C) Enhanced osteoclastogenesis in c/ebpbeta mutant mice. TRACP staining of osteoclasts (red staining) in tibiae of 8-week-old WT and c/ebpbeta mutant mice. Lightgreen was used as counterstain. Scale bar, 20 mum. Bar graph shows the urinary excretion of deoxypyridinoline (DPD) cross-links, reflecting osteoclast activity in vivo. For bone histomorphometric measurements, n=8 per group. +/+, WT mice; -/-, c/ebpbeta-/- mice; L/L, LIP k.i. mice. Data are presented as mean+/-s.e.m. *P<0.05, **P<0.01 versus WT.
###end p 153
###begin p 154
###xml 30 35 30 35 <italic>c/ebp</italic>
###xml 50 51 47 48 <bold>A</bold>
###xml 265 266 262 263 <bold>B</bold>
###xml 472 477 469 474 <italic>c/ebp</italic>
###xml 481 484 475 478 <sup>&#8722;/&#8722;</sup>
###xml 491 492 485 486 <italic>L</italic>
###xml 493 494 487 488 <italic>L</italic>
###xml 496 499 490 493 <italic>LIP</italic>
###xml 547 548 539 540 <sup>*</sup>
###xml 548 549 540 541 <italic>P</italic>
###xml 461 465 <span type="species:ncbi:10090">mice</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
###xml 505 509 <span type="species:ncbi:10090">mice</span>
Osteoblast differentiation in c/ebpbeta mutants. (A) Primary calvarial osteoblast precursor cells were differentiated and stained for alkaline phosphatase (ALP) activity. The bar graph displays the quantification of the percentage ALP positive area per well area. (B) Bone nodule mineralization of primary calvarial osteoblasts determined by alizarin red staining. The bar graph displays the quantification of alizarin red positive mineralized nodules. +/+, WT mice; -/-, c/ebpbeta-/- mice; L/L, LIP k.i. mice. Data are presented as mean+/-s.e.m. *P<0.05, versus WT.
###end p 154
###begin p 155
###xml 36 41 36 41 <italic>c/ebp</italic>
###xml 56 57 53 54 <bold>A</bold>
###xml 356 357 347 348 <bold>B</bold>
###xml 513 514 504 505 <bold>C</bold>
###xml 680 685 668 673 <italic>c/ebp</italic>
###xml 689 692 674 677 <sup>&#8722;/&#8722;</sup>
###xml 699 700 684 685 <italic>L</italic>
###xml 701 702 686 687 <italic>L</italic>
###xml 704 707 689 692 <italic>LIP</italic>
###xml 755 756 738 739 <sup>*</sup>
###xml 756 757 739 740 <italic>P</italic>
###xml 607 611 <span type="species:ncbi:10090">mice</span>
###xml 669 673 <span type="species:ncbi:10090">mice</span>
###xml 693 697 <span type="species:ncbi:10090">mice</span>
###xml 713 717 <span type="species:ncbi:10090">mice</span>
Osteoblast-osteoclast cross-talk in c/ebpbeta mutants. (A) Expression of the osteoclastic regulators RANK-L, OPG and TNFalpha in primary calvarial osteoblast cultures as determined by real-time RT-PCR. Values represent relative expression levels compared with WT on day 14 (set as 1). Data are presented as mean+/-s.e.m. of three independent experiments. (B) Number of multinucleated osteoclasts formed from WT bone marrow cells (BM) co-cultured with osteoblasts (OB) from the different genotypes, as indicated. (C) Number of multinucleated osteoclasts formed from bone marrow cells of the C/EBPbeta mutant mice (as indicated), co-cultured with WT osteoblasts. +/+, WT mice; -/-, c/ebpbeta-/- mice; L/L, LIP k.i. mice. Data are presented as mean+/-s.e.m. *P<0.05 versus WT.
###end p 155
###begin p 156
###xml 0 5 0 5 <italic>c/ebp</italic>
###xml 57 58 54 55 <bold>A</bold>
###xml 140 145 137 142 <italic>c/ebp</italic>
###xml 164 167 158 161 <italic>LIP</italic>
###xml 403 404 397 398 <bold>B</bold>
###xml 701 702 695 696 <bold>C</bold>
###xml 1026 1027 1018 1019 <italic>n</italic>
###xml 1041 1042 1033 1034 <sup>*</sup>
###xml 1042 1043 1034 1035 <italic>P</italic>
###xml 1050 1052 1042 1044 <sup>**</sup>
###xml 1052 1053 1044 1045 <italic>P</italic>
###xml 1060 1063 1052 1055 <sup>***</sup>
###xml 1063 1064 1055 1056 <italic>P</italic>
###xml 1083 1084 1075 1076 <bold>D</bold>
###xml 1427 1432 1415 1420 <italic>c/ebp</italic>
###xml 1436 1439 1421 1424 <sup>&#8722;/&#8722;</sup>
###xml 1446 1447 1431 1432 <italic>L</italic>
###xml 1448 1449 1433 1434 <italic>L</italic>
###xml 1451 1454 1436 1439 <italic>LIP</italic>
###xml 173 177 <span type="species:ncbi:10090">mice</span>
###xml 485 491 <span type="species:ncbi:9913">bovine</span>
###xml 1416 1420 <span type="species:ncbi:10090">mice</span>
###xml 1440 1444 <span type="species:ncbi:10090">mice</span>
###xml 1460 1464 <span type="species:ncbi:10090">mice</span>
c/ebpbeta mutations promote osteoclast differentiation. (A) Osteoclast differentiation of bone marrow derived monocytic precursors from WT, c/ebpbeta knock-out and LIP k.i. mice and treated with M-CSF and RANK-L. Osteoclasts were stained by TRACP activity (red staining). The bar graph displays the differential quantification of the osteoclasts by number of nuclei per cell (WT cultures set at 100%). (B) Bone resorptive activity of osteoclasts determined by culturing osteoclasts on bovine bone slices and staining resorption pits (arrowheads) with coomassie brilliant blue. The bar graph displays the quantification of the resorption areas expressed as fold of resorbed area in the WT (set at 1). (C) Real-time RT-PCR analysis of expression of the osteoclast markers TRACP, Cathepsin K (CathK), calcitonin receptor (CTR), OSCAR and DC-STAMP in osteoclasts cultured for 6 days in the presence of M-CSF and RANK-L. Values represent relative expression levels compared with WT (set as 1). Data are presented as mean+/-s.e.m.; n=6 per group. *P<0.05, **P<0.01, ***P<0.001 versus WT. (D) Western blot analysis of cleaved-caspase 3 (cl. caspase 3) expression to determine apoptosis in primary osteoclasts cultured for 6 days in the presence of M-CSF and RANK-L. The samples were run on the same gel, but were noncontiguous, as indicated with the black lines. Loading was controlled by alpha-tubulin expression. +/+, WT mice; -/-, c/ebpbeta-/- mice; L/L, LIP k.i. mice.
###end p 156
###begin p 157
###xml 104 105 101 102 <bold>A</bold>
###xml 637 638 634 635 <bold>B</bold>
###xml 698 699 692 693 <sup>*</sup>
###xml 1048 1049 1035 1036 <bold>C</bold>
###xml 1325 1326 1309 1310 <bold>D</bold>
###xml 1386 1387 1367 1368 <sup>*</sup>
###xml 1644 1649 1622 1627 <italic>c/ebp</italic>
###xml 1653 1656 1628 1631 <sup>&#8722;/&#8722;</sup>
###xml 1663 1664 1638 1639 <italic>L</italic>
###xml 1665 1666 1640 1641 <italic>L</italic>
###xml 1668 1671 1643 1646 <italic>LIP</italic>
###xml 1633 1637 <span type="species:ncbi:10090">mice</span>
###xml 1657 1661 <span type="species:ncbi:10090">mice</span>
###xml 1677 1681 <span type="species:ncbi:10090">mice</span>
The mammalian target of rapamycin (mTOR) regulates osteoclastogenesis by switching C/EBPbeta isoforms. (A) Representative pictures of primary bone marrow derived monocytic precursors from indicated genotypes differentiated into osteoclasts in the absence (solvent) or presence of rapamycin. Osteoclasts were stained for TRACP after 6 days (red staining). Bar graphs show quantification of differentiated osteoclasts (by number of nuclei per cell). The values from WT cultures was set at 100% (indicated as dashed line). Note the difference in scale between the results from WT and mutant cultures. A representative experiment is shown. (B) Western blot analysis of C/EBPbeta isoform expression (LAP*, LAP and LIP) in primary osteoclasts treated with rapamycin (Rap), as indicated. Positive control consisting of mature osteoblasts (mOB) is shown to indicate the different C/EBPbeta isoforms. The positive control was run on the same gel, but was noncontiguous, as indicated with the black line. Loading was controlled by alpha-tubulin expression. (C) Representative pictures of RANK-L-induced osteoclast differentiation in RAW264.7 cells stably expressing the indicated C/EBPbeta isoforms or EGFP control. Osteoclasts were stained for TRACP (red staining). Arrowheads indicate small osteoclasts present in the LAP cultures. (D) Western blot analysis of C/EBPbeta isoform expression (LAP*, LAP and LIP) in RAW264.7 cells stably expressing the C/EBPbeta isoforms LAP or LIP, or EGFP (as control) and differentiated into osteoclasts. The lanes were run on the same gel, but were noncontiguous as indicated with the black lines. +/+, WT mice; -/-, c/ebpbeta-/- mice; L/L, LIP k.i. mice.
###end p 157
###begin p 158
###xml 72 73 69 70 <bold>A</bold>
###xml 353 354 350 351 <bold>B</bold>
###xml 404 409 401 406 <italic>c/ebp</italic>
###xml 413 416 407 410 <sup>&#8722;/&#8722;</sup>
###xml 421 424 415 418 <italic>L/L</italic>
###xml 644 645 638 639 <bold>C</bold>
###xml 714 719 708 713 <italic>c/ebp</italic>
###xml 723 726 714 717 <sup>&#8722;/&#8722;</sup>
###xml 731 734 722 725 <italic>L/L</italic>
###xml 905 906 894 895 <italic>n</italic>
###xml 920 921 909 910 <sup>*</sup>
###xml 921 922 910 911 <italic>P</italic>
###xml 929 931 918 920 <sup>**</sup>
###xml 931 932 920 921 <italic>P</italic>
###xml 950 951 939 940 <bold>D</bold>
###xml 1179 1180 1165 1166 <bold>E</bold>
###xml 1398 1399 1384 1385 <bold>F</bold>
###xml 1623 1624 1601 1602 <sup>*</sup>
###xml 1624 1625 1602 1603 <italic>P</italic>
###xml 1648 1649 1626 1627 <bold>G</bold>
###xml 2179 2180 2157 2158 <bold>H</bold>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
###xml 987 992 <span type="species:ncbi:10090">mouse</span>
###xml 1129 1132 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1216 1221 <span type="species:ncbi:10090">mouse</span>
###xml 1452 1457 <span type="species:ncbi:10090">mouse</span>
C/EBPbeta isoforms regulate osteoclastogenesis through MafB expression (A) Venn diagram and number of differentially regulated genes in RAW264.7 cells induced to differentiate into osteoclasts for 2 days as identified by gene array analysis. Control cells (empty vector) and cells stably expressing LAP were compared with cells treated with rapamycin. (B) Real-time RT-PCR analysis of MafB expression in c/ebpbeta-/- and L/L osteoclasts cultured for 2 days with M-CSF and RANK-L as well as in the absence (grey bars) or presence of rapamycin (green bars), as indicated. Values represent relative expression levels compared with WT (set as 1). (C) Real-time RT-PCR analysis of MafB expression in osteoclasts of WT, c/ebpbeta-/- and L/L mice cultured for 6 days under osteoclastogenic conditions. Values represent relative expression levels compared with WT (set as 1). Data are presented as mean+/-s.e.m.; n=6 per group. *P<0.05, **P<0.01 versus WT. (D) Luciferase reporter assay using a mouse MafB promoter reporter. RAW264.7 cells were transfected with empty control (EGFP) or with C/EBPbeta isoforms. Values were normalized to CMV-promoter driven Renilla luciferase activity. (E) Luciferase reporter assay using a mouse MafB promoter reporter. RAW264.7 cells were transfected with empty control (EGFP) or LAP expression vector, treated with RANK-L and with rapamycin (green bars), as indicated. (F) C/EBPbeta-deficient MEFs were transfected with the mouse MafB promoter reporter and control (empty vector, EGFP) or C/EBPbeta (WT) and treated with rapamycin (green bars), as indicated. Data are presented as mean+/-s.e.m, *P<0.05 versus control. (G) Representative pictures of RANK-L-induced osteoclast differentiation of RAW264.7 cells with stable MafB short hairpin interfering RNA (shMafB) or control, in the absence (solvent) or presence of rapamycin, as indicated. Osteoclasts were stained for TRACP (red staining). Bar graphs show quantification of differentiated osteoclasts (number of nuclei per cell), in the absence (solvent) or presence of rapamycin. The values from control cultures in the presence of solvent are set at 100%. A representative experiment is shown. (H) Knock-down of MafB using a shRNA in RAW264.7 cells as determined by western blot analysis. The lanes were run on the same gel, but were noncontiguous. Loading was controlled by analysis of alpha-tubulin expression.
###end p 158
###begin p 159
###xml 514 519 504 509 <italic>et al</italic>
###xml 510 525 500 515 <xref ref-type="bibr" rid="b32">Kim <italic>et al</italic>, 2007</xref>
###xml 527 531 517 521 <xref ref-type="bibr" rid="b33">2008</xref>
C/EBPbeta as a switch in osteoclastogenesis. Schematic representation of how differences in mTOR activity alters the C/EBPbeta isoform ratio to regulate osteoclastogenesis. Rapamycin inhibits mTOR, which causes enhanced expression of LAP. LAP induces expression of MafB. MafB inhibits NFATc1 and other osteoclastic transcriptional regulators (c-Fos and Mitf), which results in the down-regulation of osteoclastic genes including TNFalpha and the cell fusion genes ATP6v0d2 and DC-STAMP (partially derived from Kim et al, 2007, 2008). Enhanced expression of LAP therefore inhibits osteoclast differentiation, whereas LIP (produced at high mTOR activity) forces osteoclast differentiation.
###end p 159

